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CHAPTER 1 
 
INTRODUCTION 
 
With the advent of new therapies for lung cancer, patients with advanced disease 
have seen an improvement in survival after a diagnosis (Ramalingam, 2011). In 2015, 
however, nearly 158,040 people will still die from lung cancer (American Cancer 
Society, 2015) because approximately 50% of patients are diagnosed at an advanced 
stage of the disease (Ramalingam, 2011). Because of improvements in survival time of 
patients with advanced lung cancer, it is imperative to investigate potential problems 
and issues specific to this population.  
Health related stigma (HRS) is a social process or related personal experience 
characterized by exclusion, rejection, blame, or devaluation that results from experience 
or reasonable anticipation of an adverse social judgment about a person or group 
identified with a particular health problem (Weiss & Ramakrishna, 2006).  HRS can be 
classified as internal or external HRS. A patient with internal HRS will blame herself or 
identify herself as the cause of the disease. For example, a patient with lung cancer 
may believe she caused her diagnosis by smoking. External HRS is directed at the 
patient from an outside source such as a healthcare provider, family caregiver, or 
someone from the general public. In external HRS, the outside source identifies the 
patient as the cause of his disease. Although almost all patients with cancer were once 
highly stigmatized due to their diagnosis, patients with certain types of cancers no 
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longer face the stigmas they once did. Patients who have cancers associated with 
certain lifestyle choices, such as lung or cervical cancer, however, continue to draw 
perceptions of blame and stigma. In these cases the disease is more prone to be seen 
as a reflection of personal responsibility (Marlow, Waller, & Wardle, 2010). Little is 
known about how internal or external HRS influences patients with advanced lung 
cancer. We do know, however, in an HIV/AIDS population HRS influences a patient’s 
overall quality of life (QOL) (Buseh, Kebler, Stevens, & Park, 2008). HRS related to 
HIV/AIDS negatively influences psychological outcomes of patients and this influence is 
independent of health status or disease related symptoms (Clark, Linder, Armistead, & 
Austin, 2003; Kang, Rapkin, Remien, Mellins, & Oh, 2005; Lee, Kochman, & Sikkema, 
2002). In an HIV population, HRS in family and healthcare settings caused more 
psychological damage than HRS from other social support settings (Slutterheim et al., 
2009). As the number of intense and graphic anti-smoking campaigns increase, stigma 
associated with smoking as well as diseases linked to smoking may also increase and 
may have a negative impact on patients who suffer from these diseases (Marlow, et al., 
2010). 
 
Statement of Problem 
 The problem of interest is internal and external HRS in patients with advanced 
lung cancer. We know that HRS has a negative influence on multiple outcomes of 
patients with HIV/AIDS including psychological outcomes and QOL (Buseh, et al., 2008; 
Clark, et al., 2003; Kang, et al., 2005; Lee, et al., 2002; Slutterheim, et al., 2009). 
Internal and external HRS may also have negative effects on patients with advanced 
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lung cancer. It has been shown that 30% of lung cancer patients blame themselves for 
their diagnosis (internal HRS) (LoConte, Else-Quest, Eickhoff, Hyde, & Schiller, 2008). It 
remains unclear how lung cancer patients perceive external HRS related to their 
disease. For this reason, there is a need to further investigate the role of HRS in 
patients with advanced lung cancer to determine if it influences physical symptoms, 
psychological symptoms, social support, QOL. Because limited research studies exist 
regarding HRS in advanced lung cancer there is a need to (1) examine the significance 
of internal and external HRS within the population, (2) examine the relationship of HRS 
to psychological and physical outcomes, and (3) examine the relationship of HRS to 
perceived social support and QOL.  
 
Purpose of the Study 
 The purpose of this dissertation study is to examine the relationship of internal 
and external HRS to physical symptoms, psychological symptoms, social support, and 
QOL in patients with advanced lung cancer. The specific aims for the proposed study 
include: 
1. To examine the relationship between internal and external HRS, physical symptoms, 
psychological symptoms, social support, and QOL in patients with advanced lung 
cancer. 
2. To examine the associations between physical symptoms and social support, and 
QOL in patients with advanced lung cancer.  
3. To examine the associations between psychological symptoms and social support 
and QOL in patients with advanced lung cancer. 
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Research Question 
1. What are the associations between internal and external HRS and (a) symptoms, (b) 
social support, and (c) QOL in patients with advanced lung cancer? 
2. What are the associations between physical symptoms and (a) social support and (b) 
QOL in patients with advanced lung cancer?  
3. What are the associations between physical symptoms and (a) social support and (b) 
QOL in patients with advanced lung cancer?  
 
Significance of the Issue to Society 
 
Significance to Society 
Incidence of Lung Cancer in the United States  
Cancer is the second leading cause of death in the United States, (American Cancer 
Society, 2015; Xu, Kochanek, Murphy, & Tejada-Vera, 2010) and the chronicity of 
terminal cancer care is a significant stressor for the entire family unit (Sydney, Compas, 
Epping-Jordan, & Worsham, 1999). In 2015, approximately 1,668,370 new cases of 
cancer will be diagnosed in the United States and approximately 589,430 Americans will 
die from their disease (American Cancer Society, 2015). Cancer now accounts for 
nearly 1 out of every 4 adult deaths in the United States (American Cancer Society, 
2015).  
Lung cancer is the second most common cancer and the leading cause of cancer-
related deaths in the United States (American Cancer Society, 2015).  In the United 
States approximately 224,210 new cases of lung cancer will be diagnosed in 2015 and 
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approximately 159,260 patients will die (American Cancer Society, 2015). The 5-year 
relative survival rate of patients with lung cancer is 3.7% (American Cancer Society, 
2015). In 2015, lung cancer will be the leading cancer diagnosis in Tennessee 
(American Cancer Society, 2015). Of the 6,200 people diagnosed with lung cancer in 
Tennessee, 4,600 will die from their disease (American Cancer Society, 2015). 
Lung Cancer and Health Related Stigma 
HRS associated with a diagnosis lung cancer has been established (Cataldo, 
Slaughter, Jahan, Pongquan, & Hwang, 2011; Chapple, Ziebland, & McPherson, 2004), 
and when compared to other types of cancer, one study showed that lung cancer 
patients have more externally perceived HRS than those with other types of cancer 
(LoConte, et al., 2008). People who engage in behaviors that may contribute to their 
cancer diagnosis experience an increase in negative attitudes and more severe 
consequences of external HRS (Lebel & Devins, 2008). Because smoking is viewed as 
a contributing yet controllable factor of lung cancer, these patients may face more 
external HRS than patients with other types of cancer or diseases (Lebel & Devins, 
2008). Self-blame attributions (internal HRS) have been found to be similar for a 
diagnosis of lung cancer or HIV (Greene & Banerjee, 2006).  
Both smokers and non-smokers feel stigmatized after of a diagnosis of lung cancer 
(Cataldo, et al., 2011; Chapple, et al., 2004) which can lead to a fear of rejection, limited 
social support, increased depression, difficulty adhering to treatment plans, and general 
poor health (Chambers, 2012). Lung cancer patients have reported their diagnosis has 
negatively affected their relationship with their family and friends as well as interactions 
with the medical community (Chapple, et al., 2004). Patients who stopped smoking and 
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those who never smoked felt unjustly blamed for having the disease and some patients 
conceal a diagnosis from loved ones, negatively affecting potential support from family 
and friends (Chapple, et al., 2004).  
 Regardless of smoking status, stigma associated with a lung cancer diagnosis is 
related to an increase in depressive symptomology. As perceived stigma increased, the 
levels of depressive symptomology increased (Gonzalez & Jacobsen, 2010). Stigma 
has also shown  a unique statistical contribution to depressive symptoms (Gonzalez & 
Jacobsen, 2010). Cataldo, Jahan, and Pongquan (2011) had similar results. The 
perception of stigma also had a negative impact on overall QOL of lung cancer patients.  
 Patients and caregivers attribute the cause of lung cancer to the patient with a 
history of smoking (Lobchuk, 2008), and caregivers feel more anger and attribute more 
blame when a patient continues to smoke after a diagnosis (Lobchuk, 2012). Negative 
emotions and blaming behaviors may cause caregivers to feel less empathy for their 
loved one and engage in fewer care activities (Lobchuk, 2012). Lack of appropriate 
caregiving at home is problematic for patients with advanced lung cancer due to the 
high number of physical and psychological symptoms experienced in this population. 
Because the majority of care for these patients is provided at home by a lay caregiver, it 
is imperative to investigate if patients perceive a stigma from their primary caregiver so 
that clinical interventions can be designed to intervene when there is a problem.  
Summary 
 Regardless of smoking status, patients with lung cancer feel stigmatized because 
of their disease. At this time, relatively little information is available on how HRS may 
influence the overall experience of patients with lung cancer. Although we know stigma 
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increases depressive symptoms in lung cancer, we do not know if internal or external 
HRS is the most influential type of stigma or if HRS has other negative or preventable 
effects in patients with lung cancer. We know that some caregivers blame the patient for 
their diagnosis and this may impact care provided at home. For this reason, we need to 
clarify how patients perceive stigma from their primary caregiver.  
Physical Symptoms  
Multiple factors influence cancer patient symptoms. Patients with lung cancer 
typically present with the same physical symptoms regardless of histology (Hopwood & 
Stephens, 1995). Higher symptom distress is associated with both late stage as well as 
recurrent disease (Degner & Sloan, 1995; Sarna, 1993). and treatment modality has the 
greatest impact on the symptom experience (Nuamah, Cooley, Fawcett, & McCorkle, 
1999; Tishman, Taube, & Sachs, 1991). In lung cancer patients, chemotherapy and 
comorbidities, especially respiratory conditions, have been shown to increase physical 
symptom burden and symptom distress (Sarna, 1993). Several demographic factors 
appear to be associated with symptom presentation in the lung cancer population 
including age(Degner & Sloan, 1995), female gender (Degner & Sloan, 1995), and 
African American race(O'Hare, Malone, Lusk, & McCorkle, 1993).  
One study suggests that lung cancer patients experience more symptoms and have 
a higher symptom distress than patients with other types of cancer (Degner & Sloan, 
1995). Symptom severity typically increases as the disease progresses (M. Cooley, 
2000) and symptom distress has been shown to predict survival in lung cancer patients 
(Degner & Sloan, 1995). The most commonly reported lung cancer symptoms are: 
fatigue, dyspnea, cough, weight loss, anorexia, pain, insomnia, mental status changes, 
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and psychological distress (M. Cooley, 2000; Yount et al., 2011). The most distressing 
symptoms for lung cancer patients are difficulty breathing, pain, and fatigue, with 
difficulty breathing identified as the most distressing symptom over time. Fatigue, 
however, is the most intense symptom experienced by lung cancer patients (Tishman et 
al., 2005). At this time it is unknown if HRS influences the experience of symptoms in 
patients with lung cancer. 
Symptom burden within this population is high (M. E. Cooley, Short, & Moriarty, 
2003). Because symptoms progress as the disease progresses, it is of particular 
importance to appropriately and adequately manage symptoms in lung cancer patients 
(M. Cooley, 2000). In a comparison study, all subgroups of lung cancer patients had a 
high prevalence of reported symptoms, but the subgroup closest to death reported a 
higher intensity of symptoms than other groups (Tishman, Petersson, Degner, & 
Sprangers, 2007). The increase in symptom intensity as the disease progresses 
indicates the goal of treatment is proactive management of symptom burden and 
improved QOL for this population (Yount, et al., 2011). 
Summary 
 Patients with lung cancer experience an extremely high number of symptoms. 
Most patients are diagnosed with late stage disease, which has been associated with a 
higher symptom burden. Patients with lung cancer may also experience more symptom 
distress than patients with other types of cancer.  
Psychological Distress and Psychological Symptoms  
Psychological distress, depression, and anxiety have been studied in oncology 
populations. Psychological distress is a discomforting and emotional state that has the 
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potential to temporarily or permanently harm an individual (Ridner, 2004). Anxiety and 
depression are the most commonly studied psychological symptomology and are 
thought to be the most prevalent disorders diagnosed within the oncology population 
(Maguire, Julier, Hawton, & Bancroft, 1974). In patients with advanced cancer these 
disorders are often under diagnosed leading to decreased QOL for patients and their 
family caregivers (Delgado-Guay, Parsons, Li, & al., 2009).   
Patients with lung cancer have been shown to have the highest rates of 
psychological distress when compared to other cancer sites (Tagay et al., 2006; Wilgen, 
Dijkstra, Stewart, Ranchor, & Roodenburg, 2006; Zabora, Brintzehofeszoc, Curbow, 
Hooker, & Piantadosi, 2001). Regardless of age, over or under 65, lung cancer patients 
report similar levels of psychological distress (Turner, Muers, Haward, & Mulley, 2007).  
Prevalence in advanced cancer populations may be as high as 29% for depression 
(Hotopf, Chidgey, & Addington-Hall, 2002) and 44% for anxiety (Delgado-Guay, et al., 
2009). The prevalence of combined depression and anxiety in a lung cancer population 
has been estimated at 21% (Hopwood & Stephens, 2000). The presence of anxiety and 
depression has been shown to significantly impair QOL in patients with lung cancer 
(Montazeri, Milroy, Hole, McEwen, & Gillis, 1998) but healthcare providers routinely 
address physical illness symptoms more frequently than psychosocial symptoms.  
Anxiety is frequently identified in newly diagnosed cancer patients although 
prevalence varies widely within the literature (Stark & House, 2000). Prevalence rates in 
a lung cancer population have been reported to be as high as 34%, with 17% of those 
having a severe anxiety (Hopwood & Stephens, 2000). 
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Severe depressive symptomology has been associated with a diagnosis of lung 
cancer (Montazeri, et al., 1998). Prevalence rates in a lung cancer population have 
been estimated at 33% (Hopwood & Stephens, 2000).  
Several factors, including social functioning, symptom severity, and radiation 
treatment, have been shown to predict depressive symptomology in lung cancer 
patients (Kurtz, Kurtz, Stommel, Given, & Given, 2002). Patients with more restricted 
social interaction and a high level of symptoms had the highest rates of depressive 
symptoms and those who did not receive radiation had more depressive symptoms 
(Kurtz, et al., 2002). Statistically significant relationships have also been found between 
depression and the following physical symptoms: tiredness, breathlessness, cough, 
general pain, and chest pain (Hopwood & Stephens, 2000). Factors found to 
independently influence depression in a lung cancer population are 1) functional 
impairment and 2) physical symptom burden (Hopwood & Stephens, 2000). 
Summary 
 Patients with lung cancer often experience high rates of depressive and anxiety 
symptoms and psychological distress may be more common in lung cancer than in any 
other type of cancer. HRS has been shown to increase the probability of depressive 
symptoms in lung cancer patients but no link between stigma and anxiety or 
psychological distress has been shown at this time. Furthermore, it is still unclear if 
internal or external stigma is the influencing factor in depressive symptomology.  
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Lung Cancer Patient Quality of Life 
Initiating care to maintain or improve QOL is an important part of managing 
advanced lung cancer.  Survival is limited by the disease process and patients have an 
extremely high physical and psychological symptom burden (Buccheri, 1998). 
In general, patients with lung cancer have low QOL scores (Akin, 2010). QOL scores 
have shown improvement in advanced lung cancer patients who receive chemotherapy 
(Bozcuk, 2006). Age and QOL prior to chemotherapy have been shown to be predictors 
of QOL in patients with advanced lung cancer who receive chemotherapy (Bozcuk, 
2006). Additionally, QOL is influenced by how manageable patients perceive their 
disease to be (Downe-Wambolt, 2006).  
Summary 
 Patients diagnosed with late stage lung cancer continue to face difficulty 
maintaining a good QOL, especially during the last few months of life. Because 
treatments are now able to extend the life of more patients with advanced disease, it is 
important to find ways to maintain or improve QOL in patients who are non-curable.   
Social Support  
Three main types of social support interactions are: emotional support, informational 
support, and instrumental support (House, 1981; House & Kahn, 1985; Kahn & 
Antonucci, 1980). The perception of emotional support from family is associated with 
better social and emotional adjustment (Zemore & Shepel, 1989) and one study 
identified emotional support as the most helpful type of social support if present and the 
most damaging if absent (Dakof & Taylor 1990). For women with advanced breast 
cancer, the perception of emotional support from family was linked to a more favorable 
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outlook (Bloom & Spiegel, 1984). Informational support was most helpful from a 
physician and harmful if lacking in the clinical setting (Dakof & Taylor, 1990). 
Instrumental support was important for patients with a poor prognosis (Dakof & Taylor, 
1990).  
The lay public has misconceptions about the social support needs of cancer patients 
(Peters-Golden, 1982). Healthy controls wanted to “cheer up” the patients while patients 
said the “unrelenting optimism” of others was disturbing. When friends avoid the patient, 
however, this is particularly harmful to perceptions of support (Dakof & Shelley, 1990). 
Emotional support is positively correlated with reduced distress during the initial 
diagnosis of cancer and predicted survival in female breast cancer patients with local 
disease (Ell, Nishimoto, Mediansky, Mantell, & Hamovitch, 1992).  
The psychosocial needs of patients with lung cancer remain relatively unknown 
(Carlsen, Jensen, Jacobsen, Krasnik, & Johansen, 2005) We do know they have many 
unmet supportive care needs (Hill, Amir, Muers, Connolly, & Round, 2003; Li & Girgis, 
2006; Sanders, Bantum, Owen, Thorton, & Stanton, 2010) including social support and 
emotional and physical support needs. Among patients with lung cancer, those with the 
highest amount of unmet social support needs have the highest physical symptom 
burden and psychological distress (Sanders, et al., 2010). For patients with lung cancer, 
this means that those who suffer the most and who need the most help are not 
receiving adequate support. Limited studies show social support in the lung cancer 
population has been associated with a relief from depressive symptomology and non-
directive instrumental support has been linked with better adaptation to a lung cancer 
diagnosis (Walker, Zona, & Fisher, 2006). The impact of social support on QOL in a 
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lung cancer population is unclear (Henoch, Bergman, Gustafsson, Gaston-Johansson, 
& Danielson, 2007). 
Summary 
 Little is known about the social support needs of patients with lung cancer. 
Benefits of social support have been seen in other cancer populations, and social 
support may also be beneficial to patients with lung cancer. Stigma, however, may 
strongly influence the amount and types of social support these patients receive. It is 
unclear if stigma has a negative influence on social support within this population.  
Cost to Patients, Caregivers, and Society 
Financial costs. Among all cancers, lung cancer carries one of the largest 
national expenditures. Approximately $10.32 billion dollars are spent on lung cancer 
treatments annually (National Cancer Institute, 2010). The majority of this cost occurs 
during the initial care phase and last year of life (National Cancer Institute, 2010). A 
relatively small portion of the total cost of lung cancer care occurs during the continuing 
care phase because of the short life expectancy for the majority of lung cancer patients.  
The number of patients with lung cancer who are diagnosed at stage IIIB or stage IV 
and who receive chemotherapy has increased regardless of age (Surveillance 
Epidemiology and End Results (SEER) Program, 2011). The greatest percentages of 
expenditures for the care of lung cancer occurs in the first year after diagnosis and 
includes hospitalizations (33.6%) and other services (26.1%) not related to cancer 
treatment (Warren et al., 2008) which can be attributed to the high incidence of 
symptoms these patients experience compared to other types of cancer.     
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Other costs. Cost of treatment is not the only expense to patients and their 
caregivers facing a lung cancer diagnosis. The burden of cancer, or caring for a loved 
one with cancer, has a high psychological, emotional, and physical toll. Lung cancer has 
the greatest loss of revenue for loss in time and economic productivity when compared 
to all other cancer sites (Bradley et al., 2008). The loss of productivity for lung cancer 
patients has been estimated at $36.13 billion dollars each year. The next highest loss of 
productivity is for breast cancer, and is estimated at $12.10 billion dollars annually 
(Bradley, et al., 2008). 
Despite the obvious high economic burden of lung cancer in the United States and 
the fact that more Americans die from lung cancer every year than any other type of 
cancer, research on the disease from the NIH lags behind other types of cancer. In 
2010, $281.9 million dollars was awarded from NIH for lung cancer research compared 
to $631.2 million for breast cancer and $300.5 million for prostate cancer (National 
Cancer Institute, 2010).  
 
Significance to Healthcare 
Decrease Cost of Medical Care 
The majority of expenditures for lung cancer are hospitalizations and services 
rather than treatment related cost (Warren, et al., 2008). Compared to other types of 
cancer, more money is spent within the healthcare system for other necessary 
hospitalizations in lung cancer than in any other type of cancer (Warren, et al., 2008). 
Hospitalizations take an enormous amount of resources including physical space, 
medical staff, use of medical equipment, and supplies. Improved care options for lung 
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cancer patients may decrease the cost to the health care community by decreasing the 
amount of resources required per patient.  
Improved Palliative Care 
Both private and public health arenas have a vested interest in improving care for 
patients with advanced disease and their caregivers because of the high caregiver 
burden, the effect on personal and national financial resources, and the impact on the 
healthcare system. In order for patients and their families to achieve optimal outcomes 
there is a need for access to alternative supportive care programs that offer physical 
and emotional support for advanced cancer populations (Mazanec et al., 2009) 
Recommendations have been set forth by both the World Health Organization (World 
Health Organization, 2007) and the National Consensus Project for Quality Palliative 
Care (National Consensus Project for Quality Palliative Care, 2009) to integrate 
palliative care with oncology care services from the time of a terminal diagnosis through 
death. A recent study published in the New England Journal of Medicine (Temel et al., 
2010), demonstrated that patients receiving early palliative care as an integral 
component of their oncologic care had improved QOL, fewer depressive symptoms, and 
increased survival. Of note, patients receiving palliative care services used less 
“inappropriately aggressive” end-of-life care as defined by American Society of Clinical 
Oncology (ASCO) quality parameters. 
 
Significance to Nursing 
 The American Nurses Association (ANA) defines nursing as “the protection, 
promotion, and optimization of health and abilities, prevention of illness and injury, 
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alleviation of suffering through the diagnosis and treatment of human response, and 
advocacy in the care of individuals, families, communities, and populations” (American 
Nurses Association, 2011). For patients with lung cancer, nurses promote interventions 
that prevent or treat symptoms and act as advocates to connect patients with important 
resources in the community such as support groups, nutrition support, or social work.  
Nurses frequently collaborate with other healthcare professionals. They assess for 
problems and coordinate care as well during the administration of chemotherapy. Nurse 
practitioners also serve as an important role by diagnosing and managing symptoms 
associated with disease and treatment.  
The Oncology Nursing Society (ONS) identifies the unique and significant 
involvement that nurses provide to oncology (Oncology Nursing Society, 2009). In 
addition to patient care, nurses also contribute substantially to the advancement of 
research. The 2009 – 2013 ONS research agenda identifies several areas as priorities 
for oncology nursing research including an in-depth understanding for cancer related 
symptoms. End of Life (EOL) is also a priority research area for ONS and is particularly 
relevant within a lung cancer population due to the high mortality associated with the 
disease. The primary EOL research focus includes expanding the understanding of 
symptoms and symptom management for EOL patients and promoting and improving 
QOL for both patients and their families facing EOL. Finally, ONS recognizes the 
importance of research in the area of psychosocial and family issues. Research in this 
area is to include reducing negative outcomes, such as depression or symptom burden, 
and improving positive outcomes, such as QOL, in both patients and family caregivers.  
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 As educators, nurses can reduce the stigma after diagnosis of lung cancer and 
provide information about optimal care for symptoms at home. Nurses can also educate 
patients and their families about connections within the community to bolster social 
support which is especially important in rural clinics where other types of healthcare 
workers, such as social workers, are not readily available. 
 
Summary and Gaps 
Significant gaps exist in the lung cancer literature regarding stigma. Some evidence 
suggest the depression and stigma may be linked in a lung cancer population; we do 
not know, however, how perceived stigma may influence anxiety or psychological 
distress. HRS may lead to fewer available social supports for patients with lung cancer. 
Unlike patients with other cancers with large and widely visible support campaigns, like 
breast cancer, lung cancer patients may feel shunned, and supports may not exist 
because of the stigma associated with the disease. If patients’ perceived stigma 
influences how they interact with nurses and other healthcare workers, they may not 
ask for needed social supports  
It is important to study stigma in a lung cancer population because of the large 
number of people, both smokers and non-smokers, who are diagnosed with and die 
from the disease every year. Care for lung cancer is costly it is currently unclear what 
factors contribute to positive and negative symptom management experiences within 
this population. Because stigma has been shown to contribute to poor outcomes in 
other patient populations, such as HIV/AIDS, it is possible that it also contributes 
negatively to the lung cancer experience.  
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CHAPTER II 
 This section reviews the problem as it relates to the theoretical framework and the 
key concepts of the theoretical framework are discussed.  Current literature is reviewed 
extensively, critically analyzed, and synthesized.  
 
Theoretical Framework 
Introduced as a “work-in-progress” in 1995, the Theory of Unpleasant Symptoms 
was updated in 1997 to its current form and includes three main components: 
influencing factors, symptoms, and performance (consequences of the symptom 
experience) (Lenz, Pugh, Milligan, Gift, & Suppe, 1997). The original model depiction 
was updated to include multiple symptoms rather than one symptom because 
symptoms rarely occur in isolation. The following figure is the current picture model of 
the Theory of Unpleasant Symptoms (see Figure 1).  
Figure 1. The Theory of Unpleasant Symptoms (Lenz, et al., 1997). 
 
 
  
19 
 
Influencing factors (stigma, social support, psychological distress, depression, anxiety) 
 The Theory of Unpleasant Symptoms assumes that there are three influencing 
factors that affect a patient’s symptoms: physiologic factors, psychologic factors, and 
situational factors. Each of these three factors interacts with one other to exert influence 
over symptoms. The psychologic factors are a person’s mood or mental state. 
Psychologic factors also include an individual’s affective response to illness and the 
degree of knowledge and uncertainty about symptoms and their meaning. Situational 
factors refer to aspects of a person’s social and physical environment that may affect 
the way a patient experiences or reports symptoms. Physiologic factors refer to 
normally functioning body systems, abnormal pathology, and the energy level of an 
individual. 
 In the proposed study, psychological factors, such as psychological distress, and 
situational factors, such as internal or external stigma or social support, may directly 
influence the patient’s symptoms and symptom burden. Rapid changes in physiological 
function, such as pulmonary function, due to decline of lung cancer patients, may also 
contribute to the symptom experience.  
Stigma (internal and external), the primary concept of interest in this proposal, is a 
situational factor that has been modified in other diseases, such as breast cancer and 
HIV/AIDS, through clinical psychoeducational interventions. Influencing the patient 
perception of lung cancer related internal and external stigma may directly impact the 
patient symptom burden and indirectly QOL. Modifying perceptions of lung cancer 
related stigma may also be a way to decrease depressive symptoms or anxiety caused 
by feelings of guilt associated with causing the disease. 
  
20 
 
Symptoms (Dyspnea, pain, fatigue, etc.) 
Symptoms are the main focus of the Theory of Unpleasant Symptoms. The 
updated theory addresses both symptom clusters as well as single symptoms because 
symptoms are thought to be a multidimensional experience. There are four domains to 
each symptom that, although separate, are still related to one another. The domains 
are: 1) intensity (strength or severity), 2) timing (duration and frequency of occurrence), 
3) level of distress perceived (degree of discomfort or bothersomeness), and 4) quality.   
Physical symptoms of lung cancer patients will be assessed according to intensity 
and level of distress perceived within the proposed study. At present there are no 
known measures that address all four domains of symptoms in a lung cancer 
population. Lung cancer symptom research provides little description of symptoms that 
patients experience in clusters and which domains of the experienced symptoms are 
most important to the patient’s subjective symptom experience. Psychological 
symptoms will be measured with the Hospital Anxiety and Depression Scale. 
Performance 
The outcome of the Theory of Unpleasant Symptoms is performance. 
Conceptually defined, performance includes both functional activities, such as physical 
activity, ADLs, social interactions and role performance, and cognitive activities, such as 
concentrating, thinking, and problem solving.  In the Theory of Unpleasant Symptoms, 
performance can influence both the symptom experience and the three influencing 
factors. In the proposed study, quality of life and social dependency will be examined as 
the effects of lung cancer related symptoms.  
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Definition of Terms  
The key concepts related to the phenomenon include health related stigma, 
symptoms, symptom burden, quality of life, psychological distress, and social supports. 
Definitions of key concepts are defined as follows (see Table 1). 
Table 1 Key Concepts Related to the Phenomenon 
Key Concepts Definition Related to the Phenomenon 
Health 
Related 
Stigma 
Health related stigma is a social 
process or related personal 
experience characterized by 
exclusion, rejection, blame, or 
devaluation that results from 
experience or reasonable 
anticipation of an adverse social 
judgment about a person or 
group identified with a particular 
health problem (Weiss & 
Ramakrishna, 2006). 
External stigma relates to the 
perceptions of rejection or blame 
patients may feel from others 
related to a lung cancer 
diagnosis. Internal stigma relates 
to the perceptions of rejection or 
blame a patient feels from 
himself related to a lung cancer 
diagnosis.  
Symptoms A symptom is subjective 
evidence of disease or physical 
disturbance. It indicates a bodily 
disorder (Mirriam-Webster's 
Medical Dictionary, 2011). 
Symptoms related to the 
phenomenon include physical 
symptoms (pain, fatigue, etc.) 
and psychological symptoms 
(depression, anxiety) as 
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Symptoms are a subjective 
experience linked to personal 
appraisal (Liehr, 2005) and are 
often defined as either physical 
or psychological (Kroenke, 
2003). 
subjectively felt and reported by 
the patient. 
Quality of Life 
(QOL) 
Quality of life is an overall sense 
of well-being that an individual 
perceives within the context of 
their personal cultural and value 
system. Quality of life is a 
multidimensional concept based 
on patient self-assessment, on 
the interaction between a 
person’s physical health, 
psychological state, personal 
beliefs, social relationships and 
the environment. Self-report 
questionnaires are typically used 
in medical studies to measure 
an individual’s quality of life 
Quality of life, as related to the 
phenomenon, is the overall 
quality of life from the perspective 
of patients.  
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(Murphy, Herrman, Hawthorne, 
PInzone, & Evert, 2000). 
Psychological 
Distress 
Psychological distress is the 
unique discomforting and 
emotional state caused by an 
individual’s response to a 
specific stressor that has the 
potential to temporarily or 
permanently harm the individual 
(Ridner, 2004).  
Psychological distress is related 
to the phenomenon as the 
emotional response of patients to 
a lung cancer diagnosis and 
stigma related to a lung cancer 
diagnosis.  
Social 
Supports 
Social support can have many 
meanings. Here, social support 
is defined as either the 
perceived or actual physical, 
material, psychological, or 
symbolic resources that have 
health related benefits (Cohen, 
Underwood, & Bottlieb, 2000). 
Social supports can be derived 
from personal, medical, or 
community resources.  
The social supports related to the 
phenomenon are the perceived 
or actual supports that patients 
are able to identify and gain 
access to after a lung cancer 
diagnosis.  
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Critical Analysis of the Literature 
 
Stigma in Lung Cancer 
Although research on stigma has been extensive in other areas of healthcare 
such as HIV/AIDS (Buseh, et al., 2008; Clark, et al., 2003; Kang, et al., 2005; Lee, et al., 
2002; Slutterheim, et al., 2009), it is limited in the lung cancer literature.  Over the last 
several years researchers have begun to understand that HRS may play a role in the 
experience of the patient with lung cancer and an increasing number of studies have 
been published in this area. Table 2 reviews published literature that examine HRS in 
lung cancer and studies are then summarized. 
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Table 2 Analysis of Methods Used to Study Stigma in Lung Cancer 
Study Design Sample Methods Analysis Findings 
Brown-
Johnson, 
Brodsky & 
Cataldo (2015) 
Cross sectional, 
descriptive 
design 
n=149 
 
Mean age=56.8 
years 
 
93% Caucasian 
 
80% former 
smokers 
 
75.2% Female 
Cataldo Lung 
Cancer Stigma 
Scale 
 
Spielberger 
State Anxiety 
Scale 
 
CES-D 
 
Quality of Life 
Inventory 
Univariate Analysis 
 
Correlations 
 
Hierarchical 
regression 
Relationship between 
QOL and anxiety (p<0.01) 
and depression (p<0.01) 
 
Stigma plays a unique 
role in QOL (p=0.015) 
 
No relationship between 
depression and QOL and 
smoking status 
Brown & 
Cataldo (2013) 
Qualitative  
 
n=8 
Former and never 
smokers 
100% Female 
One-on-one 
interviews and 
focus groups 
Open ended 
interview format 
Discourse analysis 
 
Unvoiced precursors—
tobacco industry and 
addiction influence 
Perception of lung cancer 
stigma—diagnosis and 
interaction with 
healthcare providers 
Perception of stigma—
shifting identities  
Response to stigma—
information control, 
advocacy 
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Carter-Harris 
(2015) 
Cross-sectional, 
descriptive 
design 
n=93 
Convenience 
Sample  
62.4% Female 
82.8% Caucasian  
46.2% Stage IV 
32.3% Never 
smoker 
Cataldo Lung 
Cancer Stigma 
Scale 
Self-report dates 
 
Pearson correlations 
One-way ANOVA 
Mean days from first 
symptom to doctor visit 
41 days 
No significant difference 
between smoking status 
and perceived stigma 
Positive correlations 
between number of days 
to seeking treatment and 
stigma and blame 
(p<0.05), social isolation 
(p<0.05), and smoking 
(p<0.05) 
Cataldo & 
Brodsky (2013) 
Cross-sectional, 
descriptive 
design 
n=144 
Mean age=57 
years 
93% Caucasian  
79% Current or 
former smoker 
74% Female 
Cataldo Lung 
Cancer Stigma 
Scale  
Speilberger 
State Anxiety 
Questionnaire 
CES-D 
Lung Cancer 
Symptom Scale 
Univariate analysis 
Correlations 
Hierarchical multiple 
regression 
Significant relationship 
between stigma and 
anxiety (r=0.413, 
p<0.001), depression 
(r=0.559, p<0.001), and 
symptom severity 
(r=0.483, p<0.001) 
Stigma played a unique 
role in the stigma 
experience (p<0.05) 
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Cataldo, Jahan 
& Pongquan 
(2012) 
Cross-sectional, 
descriptive 
design 
n=190 
Mean age=55.05 
years 
85.2% Caucasian 
67.9% Married 
79.5% Ever 
smokers 
Cataldo Lung 
Cancer Scale 
CES-D 
Quality of Life 
Inventory 
Correlations 
Multiple regression 
Significant correlations 
were found between 
stigma and depression 
(r=0.68, p<0.001) and 
QOL (r=-0.65, p<0.001) 
LCS provides a unique 
and significant 
explanation of the 
variance of QOL over and 
above that of 
depression, age, gender, 
and smoking status, by 
2.1% (p < 0.001) 
Chambers et 
al. (2015) 
Pre/Post Test, 
Phase I trial 
Cognitive 
behavioral 
intervention 
n=14 
Mean age=62.15 
years 
88% Female 
52% Not currently 
smoking 
HADS 
Impact of Events 
Scale 
CES-D 
Cataldo Lung 
Cancer Stigma 
Scale 
Functional 
Assessment of 
Cancer 
Therapy—Lung 
(FACT-L) 
Interpretive 
phenomenonologcal 
analysis 
Independent sample 
t-tests 
Mann-Whitney tests 
Chi-squared tests 
Partial Eta squared 
Identified themes: the 
Therapeutic 
Relationship; Self-
management of Distress; 
Family 
Relationships 
improvements were 
observed in psychological 
(ηp2=0.182) and cancer-
specific 
distress (ηp2=0.056); 
depression (ηp2=0.621); 
health-related stigma 
(ηp2=0.139) 
 
Quality of life 
declined (ηp2=0.023) 
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Chapel, 
Zeibland & 
McPherson 
(2004) 
Cross-sectional n=45 
Age range=50-61 
Purposeful 
sampling 
99% Caucasian 
Qualitative 
Face-to-face 
unstructured 
interviews 
NUD*IST software 
was use to code 
interviews 
Both smothers and non-
smokers felt a stigma due 
to lung cancer  
Feelings of internal and 
external stigma 
associated with a lung 
cancer diagnosis affected 
the way lung cancer 
patients interacted with 
family, friends, and their 
physician 
Gonzalez & 
Jacobsen 
(2010) 
Cross-sectional, 
descriptive 
design 
n=95 
Mean age=64 
years 
Stage IV 66.3% 
92.6% Caucasian  
71.6% Former 
smoker 
Social Impact 
Scale 
Coping 
Responses 
Inventory—
Cognitive 
Avoidance 
Subscale 
ENRICHD Social 
Support 
Instrument 
Dysfunctional 
Attitudes Scale 
Correlations 
Hierarchical 
regressions 
Positive correlation 
between the perception of 
stigma and depressive 
symptoms (p<.001) 
 
Stigma was a unique 
contributor to depressive 
symptomology beyond 
what was accounted for 
by demographic, clinical, 
and psychosocial factors 
(3%, p=0.043) 
 
Two SIS subscales 
accounted for significant 
variability in depressive 
symptomology, the 
Financial Insecurity 
subscale (3%, p<0.036) 
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CES-D and the Social Isolation 
subscale (7%, p<0.001). 
Gonzalez & 
Jacobsen 
(2012) 
Cross-sectional, 
descriptive 
design 
n=95 
Mean age=64.04 
Stage IV 66.3% 
92.6% Caucasian  
71.6% Former 
smoker 
 
 
Social Impact 
Scale 
Coping 
Responses 
Inventory—
Cognitive 
Avoidance 
Subscale 
ENRICHD Social 
Support 
Instrument 
Dysfunctional 
Attitudes Scale 
CES-D 
Independent sample 
t-tests 
ANOVAs 
Chi-squared 
Positive association 
between stigma and 
depression (r=0.46, 
p<0.001) 
Stigma accounted for a 
unique variance in 
depression symptoms 
(β50.19, p<0.05) 
Hamann et al. 
(2014) 
Cross-sectional n=42 (individual 
interviews) 
n=23 (focus 
groups) 
Qualitative 
Semistructured 
indiividual 
interviews 
Focus groups 
Iterative coding Two main themes 
identified: perceived (felt) 
stigma and internalized 
(self) stigma 
Widespread knowledge of 
perceived stigma 
Varying degrees of 
internalized stigma 
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Lebel et al. 
(2013) 
Cross-sectional, 
descriptive 
design 
n=107 (lung 
cancer) 
n=99 (head and 
neck cancer) 
Mean age=63 
years 
Canadian-born 
More head and 
neck participants 
had recurrent 
disease (p<0.01) 
Affect Balance 
Scale 
CES-D 
Explanatory 
Model Interview 
Catalogue—a 
subscale (not 
defined) 
Illness 
Intrusiveness 
Ratings Scale 
Post-Traumatic 
Growth Inventory 
Disfigurement 
Scale 
1-item Self-
Blame Likert 
Scale 
Marlowe-Crown 
Social 
Desirability Scale 
 
Multiple regression 
analysis 
Pearson correlations 
Chi-squared 
t-tests  
 
 
Patients with lung cancer 
reported higher levels of 
self-blame (t(199) = -5.06, 
p<0.001) 
Stigma was correlated 
with disfigurement 
(r=0.43, p<0.01), illness 
intrusiveness (r=0.46, 
p<0.01), depressive 
symptoms (r=0.44, 
p<0.01), affect scale (r=   
-0.27, p<0.01) stressful 
life events (r=0.36, 
p<0.01), and social 
desirability (r= -0.16, 
p<0.05) 
Stigma correlated 
significantly with distress 
(β=0.25, p<0.001) 
Lung cancer patients 
reported higher levels of 
stigma than head and 
neck cancer patients 
(p<0.001)  
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Lehto (2014) Cross-sectional, 
descriptive 
n=11 
Mean age=69.8 
years 
Non-small cell 
lung cancer 
55% Female 
 
 
Focus groups Qualitative  
Focus group 
analysis  
Six themes emerged: 1) 
societal attitudes; 2) 
institutional 
practices and 
experiences; 3) negative 
thoughts and emotions 
such as guilt, self-blame 
and self-deprecation, 
regret, and anger; 4) 
actual stigmatization 
experiences; 5) smoking 
cessation: personal 
choices versus addiction; 
and 6) causal attributions 
LoConte et al. 
(2008) 
Longitudinal, 
descriptive study 
n=96 (lung 
cancer) 
n=30 (breast 
cancer) 
n=46 (prostate 
cancer) 
Mean age=65.6 
(lung cancer) 
All had Stage IV 
disease 
Lung cancer 
specific: 
Data collected at 
baseline, 2 
months and 6 
months 
Stigma scale 
developed for 
this study (6 
questions) 
Interviews 
Between subjects 
MANCOVA 
Two-sample t-tests 
Feelings of 
embarrassment related to 
cancer diagnosis was 
higher in patients with 
lung cancer compared to 
breast and prostate 
cancer patients (p<0.01)  
 
Generalized guilt and 
shame was not different 
between groups (p>0.05) 
 
History of smoking was 
positively correlated with 
guilt and shame for all 
tumor types (p<0.05)  
 
Lung cancer patients with 
a history of smoking had 
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93.8% Caucasian 
66.7% Married 
80.2% Former 
smoker 
higher levels of guilt and 
shame than never-
smoker lung cancer 
patients (p=0.024) 
 
Patients who perceived 
past lifestyle choices as a 
contributing factors to 
their current diagnosis 
had higher levels of guilt, 
shame, anxiety and 
depression (p<0.01). 
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Summary/Synthesis of Findings 
 Findings from these studies show that current, former, and never-smokers 
experience both internal and external stigma and embarrassment related to a diagnosis 
of lung cancer. Samples in the previously reviewed studies are primarily white and lack 
information on racially diverse populations. Stigma in lung cancer may be one important 
factor that contributes to depression though we do not know how lung cancer related 
stigma, internal or external, relates to other psychological, physiological, or 
psychosocial outcomes. Lung cancer patients may feel more embarrassment about 
their diagnosis than patients with others types of cancer because of the public 
perception of smoking as a bad life-style choice and risk factor for the disease.  
Stigma in Lung Cancer: Measurement Tools 
 Three scales have been used to assess stigma in a lung cancer population (see 
Table 3). Two of the scales, the SIS and the CLCSS, have been previously validated in 
the literature, while the third scale, which I call the PCRS, was created by the authors 
specifically for their study and has not been validated or used in any other study. There 
were no validation parameters published within the study that used the scale (See Table 
3). 
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Table 3 Measures and Scales to Study Stigma in Lung Cancer 
Instrument Concept Validity Reliability 
Perceived Cancer-
Related Stigma 
Scale (PCRS) 
-LoConte, Else-
Quest, Eickhoff, 
Hyde, & Schiller 
(2008) 
Stigma Non-validated 0.75 
Social Impact 
Scale (SIS) 
Stigma Construct 0.95 
Cataldo Lung 
Cancer Stigma 
Scale (CLCSS) 
Stigma  Construct  0.96 
  
The PCRS was developed from a focus group of lung cancer support group 
participants. It is a 6-item Likert scale intended to measure self-blame as well as 
feelings associated with guilt, shame, or embarrassment as related to cancer. Possible 
answer choices range from 1 (strongly disagree) to 5 (strongly agree). The following 
questions comprise the scale: 1) I am ashamed I got my type of cancer, 2) I deserve my 
type of cancer, 3) People judge me for my type of cancer, 4) I am embarrassed to tell 
people my type of cancer, 5) My behavior contributed to my cancer, and 6) My family 
feels ashamed of my cancer (LoConte, et al., 2008). Scores are averaged to determine 
perceived stigma.  A higher score indicates a higher perceived stigma. 
The SIS was developed as a tool to measure stigma in those with a primary 
physical illness. It was initially tested and validated in an HIV/AIDS and heterogeneous 
cancer population.  The scale consists of 24-items with four subscales. The subscales 
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of social rejection and financial insecurity are meant to measure the external experience 
of stigma and the subscales of shame and social isolation are meant to measure the 
personal internal experience of stigma. In the original study, the Cronbach alpha 
coefficient for the subscales ranges from 0.85 to 0.90 (Fife & Wright, 2000). The 
Cronbach alpha coefficient for all subscales in the lung cancer population was greater 
than or equal to 0.81 (Gonzalez & Jacobsen, 2010). 
 The CLCSS is the first and only scale to measure stigma specifically in a lung 
cancer population (Cataldo, et al., 2011). It was validated in a sample of 186 self-report 
lung cancer patients/survivors who were recruited online and who completed the scale 
as well as other measure via a secure and encrypted website, SurveyMonkey. Active 
links to the survey were placed on websites that would attract participants with lung 
cancer, including LUNGevity, the American Lung Association, Lung Cancer Alliance, 
and The American cancer Society’s Cancer Survivor Network. The final version of the 
scale contains 31 Likert items. The Cronbach alpha coefficient for the entire scale is 
0.96. The CLCSS has four subscales: 1) stigma and shame, 2) social isolation, 3) 
discrimination, and 4) smoking. The Cronbach alpha coefficient for the four subscales 
ranges from 0.75 to 0.96.  
Summary 
 The use of scales to measure stigma in a lung cancer population is very limited. 
The Social Impact Scale, however, has been used in other populations to measure 
disease-related stigma and has been shown to be both valid and reliable. Although the 
Cataldo Lung Cancer Stigma Scale was developed specifically for use in a lung cancer 
  
36 
 
population, the scale was validated online in a sample self-reported to have lung 
cancer. The scale has not been used in a clinical setting in a face-to-face format.  
Summary of Stigma in Lung Cancer 
 Although few studies examine lung cancer related stigma, those that have been 
published offer a strong argument that stigma is a problem within this population. Both 
qualitative and quantitative methods have been used. Samples are limited to primarily 
white populations and because of the low number of studies, measurement instruments 
are not consistent across studies. These findings suggest there is a need to further 
investigate stigma in a lung cancer population to determine the most appropriate 
measurement tools. 
Physical Symptoms in Lung Cancer  
Many studies have investigated physical symptoms of lung cancer patients and 
either focus on individual symptoms or on symptom clusters. Symptom clusters are two 
or more interrelated symptoms that present together , independent of other symptom 
clusters, and may or may not suggest a common etiology or underlying mechanism 
(Dodd, Miakowski, & Paul, 2001; Kim, McGuire, Tulman, & Barsevick, 2005). Recent 
research has begun to examine symptom clusters rather than isolated symptoms 
(Chan, Richardson, & Richardson, 2010; Jiminez, et al., 2001). Exemplar articles are 
presented in Table 4 and then immediately synthesized.  
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Table 4 Analysis of Methods Used to Study Symptom in Lung Cancer 
Study Design Sample Method Analysis Findings  
Iyer, Taylor-
Stokes & 
Roughley (2013) 
Record-based, 
cross-sectional 
n=1213 
Mean age=63 
years 
Male=67% 
White=93% 
Stage IIIB/IV 
Current 
smoker=45.1% 
Quit 
smoking=39.8% 
Never 
smoker=15.1% 
Non-small cell 
lung cancer 
France and 
Germany 
Lung Cancer 
Symptom Scale 
Functional 
Assessment of 
Cancer Therapy-
Lung (FACT-L) 
EuroQol (EQ-5D) 
Descriptive statistics 
Multivariate regression 
analysis 
Loss of appetite, 
fatigue, cough, pain, 
and shortness of 
breath were reported 
in ≥90% of patients 
The following were 
predictors of QOL: 
Fatigue (β= −0.122; 
p<0.001), loss of 
appetite (β= −0.170; 
p<0.001), pain (β= 
−0.145; p<0.001), 
shortness of breath 
(β= −0.118; p<0.001) 
Iyer, Roughley, 
Rider & Taylor-
Stokes (2014) 
Cross-sectional, 
descriptive 
design 
n=450 
Mean age=64.7% 
Patients and 
physicians 
Descriptive statistics 
Kappa-statistic  
Patients reported the 
following symptoms: 
Fatigue (100%), loss 
of appetite (97%), 
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White=70.9% 
Current 
smoker=34.8% 
Quit 
smoking=43.4% 
Never 
smoker=21.9% 
Stage IIIB/IV 
Non-small cell 
lung cancer 
USA 
completed 
questionnaires 
Lung Cancer 
Symptom Scale 
(LCSS) 
Functional 
Assessment of 
Cancer therapy-
Lung (FACT-L) 
Regression analysis shortness of breath 
(95%), cough (93%0, 
pain (92%), blood in 
sputum (63%) 
Concordance was 
greatest for 
hemoptysis (kappa 
0.4586) 
Concordance was 
lowest for loss of 
appetite (kappa 
0.1701) 
The following were 
significant predictors 
of QOL: Loss of 
appetite (β=−0.204; 
p<0.001), cough 
(β=−0.145; p<0.01), 
pain (β=−0.265; 
p<0.001), and 
shortness of breath 
(β=−0.145; p<0.01) 
Ma et al., (2014) Cross-sectional, 
descriptive 
design 
n=376 
Mean age=57.4 
years 
Functional 
Assessment of 
Cancer Therapy-
Lung (FACT-L) 
Descriptive statistics  
Independent t-tests 
Mann-Whitney U-test 
Patients reported 
symptoms as follows: 
loss of appetite 
(84.3%), breathing 
difficulty (79.0%) and 
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Male=63.8% 
Never 
smoker=38.8% 
Former 
smoker=10.6% 
Recently 
quit=50.6% 
China 
Stage IIIB/IV 
Cloud QOL 
System 
Pearson correlations 
Multivariate regression 
analysis  
Cough (75.5%), pain 
(53.5%) 
QOL and symptoms 
showed a significant 
correlations (p<0.001) 
All symptoms except 
shortness of breath 
was a negative 
indicator of QOL (p 
value not given) 
Degner & Sloan 
(1995) 
Cross-sectional 
descriptive 
design 
n = 82 
Consecutive 
recruitment from 
outpatient clinic 
Mean age=64.2 
Male=61% 
Advanced 
disease=72% 
Location: 
Manitoba 
Ambulatory 
cancer patients  
Medical chart 
review and face-
to-face patient 
interview 
Symptom Distress 
Scale  
Descriptive statistics 
Independent t-tests 
Pearson correlations 
Survival 
analysis/Wilcoxon 
likelihood ratio tests 
Most problematic 
symptoms are fatigue 
and insomnia. 38.9% 
and 30.9% of patients 
reported moderate to 
high levels of distress 
with these symptoms. 
Patients with 
advanced disease 
reported higher 
distress than those 
with early stage 
disease (t=-5.44, 
p=0.0001). 
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Women reported more 
distress than men (t=-
2.05, p=0.041). 
Symptom distress was 
a predictor of lung 
cancer survival 
(p=0.0001). 
Tishelman, 
Petersson, 
Degner, & 
Sprangers 
(2007) 
Longitudinal 
repeated 
measures 
descriptive 
design 
n = 400 
Consecutive 
recruitment 
Data points: prior 
to treatment, 2 
weeks, 1, 3, & 6 
months, & 1 year 
Mean age=66.2 
years 
NSCLC=85% 
Advanced 
disease=61% 
Male=52% 
Location: Sweden 
Cancer registry 
review 
Fact-to-face data 
collection 
Thurston Scale of 
Symptom 
Distress—Lung 
Cancer 
EORTC-LC13 
Relative ranking 
Kendall’s coefficient of 
agreement 
Over 50% of patients 
had problems with: 
physical role, 
emotional functioning, 
fatigue, dyspnea, and 
cough. 
In subgroups close to 
death reported 
symptoms were 
higher and function 
was lower (Physical 
function, p<0.001; 
Role function, 
p<0.001; Emotional 
function, p<0.001, 
Cognitive function, 
p<0.001; Social 
function, p<0.001; 
Fatigue, p<0.001; 
Nausea & vomiting, 
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p=0.009; Pain, 
p=0.001; Dyspnea, 
p=0.001; Insomnia, 
p<0.001). 
Relative ranking 
shows symptoms with 
the most distress 
across subgroups 
were breathing, pain, 
and fatigue.  
Cooley, Short, 
& Moriarty 
(2003) 
Longitudinal 
repeated 
measure 
descriptive 
design 
-Secondary 
analysis 
n = 117 
Data points: 
baseline, 3 & 6 
months 
recently 
diagnosed 
Mean age=64.7 
years 
White=91% 
NSCLC=86% 
Male=54% 
Early 
diagnosis=37% & 
Symptom Distress 
scale 
Descriptive statistics 
ANOVA then Fisher’s 
least significant 
differences multiple 
comparisons 
Logistic regression 
Most distressing 
symptoms at all time 
points were fatigue 
(64% at baseline, 49% 
at 3 months, 43% at 6 
months) and pain 
(56% at baseline, 32% 
at 3 months, 27% at 6 
months). 
Surgery patients 
reported pain, fatigue, 
and insomnia as the 
most distressing 
symptoms. (Pain: 69% 
at baseline, 31% at 3 
months, 40% at 6 
months; Fatigue: 57% 
  
42 
 
regional 
diagnosis=49% 
 
at baseline, 39% at 3 
months, 34% at 6 
months; Insomnia: 
57% at baseline, 30% 
at 3 months, 19% at 6 
months). 
CCR patients reported 
fatigue and pain as 
the most distressing 
symptoms. (Fatigue: 
65% at baseline, 60% 
at 3 months, 43% at 6 
months; Pain: 50% at 
baseline, 35% at 3 
months, 42% at 6 
months) 
Four patterns of 
change in symptom 
patterns: homogenous 
linear, heterogeneous 
linear, homogenous 
curvature, and 
heterogeneous 
curvature.  
Demographic 
variables did not 
predict patterns of 
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reported symptom 
distress over time. 
Tishelman et al. 
(2005) 
Longitudinal 
repeated 
measures 
descriptive 
design 
Qualitative 
analysis 
 
n = 400 
Consecutive 
recruitment 
Data points: prior 
to treatment, 2 
weeks, 1, 3, & 6 
months, & 1 year 
Mean age=66.2 
years 
NSCLC=85% 
Advanced 
disease=61% 
Location: Sweden 
Cancer registry 
review 
Fact-to-face data 
collection 
Field notes 
Thurston Scale of 
Symptom 
Distress—Lung 
Cancer 
Symptom Distress 
Scale (SDS) 
Descriptive statistics 
Relative ranking 
Review of field notes 
Relative ranking 
shows breathing, pain, 
and fatigue are 
associated with the 
most distress across 
time points. 
Fatigue on the SDS 
was rated as the most 
intense symptom 
across time points and 
was significantly 
higher than the next 
rated symptom 
(p<0.05). 
Patient comments 
from field notes show 
that breathing and 
pain are the most 
distressing symptoms. 
Jiminez et al. 
(2011) 
Cross-sectional 
descriptive 
design 
n = 437 
Consecutive 
recruitment  
Edmonton 
Symptom 
Assessment 
System 
Descriptive statistics  
Linear transformation 
Several symptom 
clusters were 
identified: confusion 
(31%), 
neuropsychological 
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Mean age=66 
Male=61% 
Multiple types of 
cancer 
Location: Hospital 
Universitario La 
Paz 
Author developed 
supplemental 
questions 
Principal component 
analysis 
(59%), anorexia-
cachexia 96%), and 
gastrointestinal (23%). 
A unique symptom 
cluster was identified 
in lung cancer 
patients: dyspnea and 
diaphoresis.  
The confusion cluster 
was more common in 
patients ≥70 
(p<0.001), and those 
with an ECOG status 
of 3 or 4 (p<0.001). 
The gastrointestinal 
cluster was more 
common in women 
(p<0.05) and in those 
with an ECOG status 
of 3 or 4 (p<0.05). 
There was no 
relationship between 
the number or location 
of metastasis and 
symptom clusters.  
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The number of 
symptom clusters 
(SC) was related to 
median survival: 52 
days for patients with 
no SC, 38 days with 1 
SC, 23 days with 2 
SCs, and 19 days with 
3 SCs (p<0.0001). 
Cooley, Short, 
& Moriarty 
(2002) 
Longitudinal 
repeated 
measures 
Secondary 
analysis 
n = 117 
Selected from 
three previously 
completed 
studies 
Mean age=64.7 
years 
White=91% 
Early stage=37% 
& regional 
stage=49% 
NSCLC=86% 
Male=54% 
Symptom Distress 
Scale 
Medical record 
review 
Descriptive statistics 
ANOVA 
Multiple regression 
models with backward 
elimination 
There were no 
significant differences 
in total symptom 
distress across 
treatment groups at 
baseline or 6 months. 
At 3 months there 
were significant 
differences in distress 
between treatment 
groups (p=0.020). The 
surgery group had 
less distress than the 
radiation therapy 
group and the 
combined therapy 
group. 
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At baseline, histology 
(p=0.023) and gender 
(p=0.009) were 
significant predictors 
of symptom distress. 
SCLC patients had 
less distress than 
NSCLC patients and 
men had less 
symptom distress than 
women. 
At three months, 
treatment modality 
(p=0.015) and nursing 
care (p=0.042) were 
significant predictors 
of symptom distress. 
Those who had 
surgery experienced 
less distress than 
those who received 
CCR or radiation 
therapy. Those with 
nursing care had less 
distress than those 
without nursing care. 
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Findings are consistent across studies. Symptom distress is high in lung cancer 
patients (Degner & Sloan, 1995; Tishman, et al., 2007). In general, pain and fatigue are 
the most distressing symptoms both at the time of diagnosis and at time points further 
from diagnosis (M. E. Cooley, et al., 2003; Degner & Sloan, 1995; Tishman, et al., 2005; 
Tishman, et al., 2007). Another consistent symptom problem in lung cancer patients is 
dyspnea/breathing (Jiminez, et al., 2001). Patients with advanced lung cancer have 
more symptoms than those diagnosed with earlier stages of the disease (Degner & 
Sloan, 1995; Tishman, et al., 2007). 
The studies presented here are all quantitative and are a mix of cross-sectional 
and longitudinal, repeated measures designs. All studies are descriptive in nature. 
Within these studies, all samples were consecutive recruited from convenient 
populations. Furthermore, the majority of these studies focused on symptoms in lung 
cancer patients with NSCLC and those who had advanced and non-curable disease. 
Study samples consist primarily of those aged 65 or older, male, and white. A number of 
studies have been conducted in countries other than the United States. 
There were no identified qualitative studies addressing symptoms in a lung 
cancer population.  
Physical Symptoms in Lung Cancer: Measurement Tools 
 Several different tools have been used to assess physical symptoms in a lung 
cancer population. The tools are presented in the following table (Table 5) and then 
discussed. 
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Table 5 Measures and Scales to Study Symptoms in Lung Cancer 
Instrument Concept Validity Reliability 
Symptom Distress 
Scale (SDS) 
Symptom Distress Construct 0.70 – 0.92 
Thurston Scale of 
Symptom 
Distress—Lung 
Cancer (TSSD-LC) 
Symptom Distress See discussion 
below 
See discussion 
below 
EORTC—LC13 QOL-Symptoms Construct/Clinical  0.70 
Edmonton 
Symptom 
Assessment 
System (ESAS) 
Symptoms Construct 0.68 to 0.80 
 The most commonly used scale in the reviewed studies was the Symptom 
Distress Scale (SDS). The SDS was developed in an outpatient oncology population 
and has been validated in the literature. This scale assesses 13 different symptoms and 
the distress associated with that symptom on a five-point Likert type scale that ranges 
from one to five (R. McCorkle & Y. Young, 1978). The symptoms assessed on this scale 
include: nausea, appetite, pain, fatigue, insomnia, bowel pattern, concentration, 
appearance, outlook, breathing, and cough. The score for the scale is a sum of the 13 
items with 13 (lowest possible score) indicating no distress and 65 (highest possible 
score) indicating severe distress. In the initial testing of this scale, reliability coefficient 
alpha for this scale was 0.82142 and the standardized coefficient alpha was 0.82557.   
 The Thurston Symptom Distress Scale—Lung Cancer uses pairwise comparison 
of nine symptoms that were identified as distressing for patients. These symptoms are 
insomnia, couch, bowel function, breathing, fatigue, pain, outlook, appetite, and 
appearance. Each of these symptoms is paired with each other for a total of 36 pairs. 
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Patients are asked to select the symptom that causes the most distress whether the 
patient is currently experiencing the symptom or not (Broberger, Tishman, & Essen, 
2005; Tishman, et al., 2005). Internal consistency was tested by calculating the number 
of circular triads or inconsistencies in participant responses. In one study, all patients, 
family caregivers, and nurses were found to be consistent in responses. The Tukey’s 
index of scalability, which accounts for response variability, was 0.94 for nurses and 
family caregivers and ranged from 0.95 to 0.98 for patient responses. The degree of 
consistency among patients, nurses, and family caregivers ranking was measured using 
Kendall’s coefficient. It was 0.29 for patients, 0.28 for nurses, and 0.21 for family 
caregivers. This indicates low to moderate levels of agreement (Broberger, et al., 2005). 
In another study, between 96.7% and 98.7% of all patients were consistent when using 
the circular triads to calculate internal consistency. The Tukey and Gulliksen index of 
scalability was between 0.95 and 0.98. The Kendall coefficient ranged from 0.24 to 
0.31, indicating low to moderate agreement between subjects (Tishman, et al., 2005).  
Part of the EORTC, the LC13 includes specific disease and treatment related 
questions. In addition to measuring overall health-related QOL, this scale measures 
disease symptoms and treatment related side effects. The scale was developed in a 
large sample of non-curable lung cancer patients recruited from 17 different countries. 
The scale has been validated within the literature for use in a lung cancer population. 
Clinical validity was assessed via known-groups comparison. The Cronbach alpha 
coefficient was >0.70 (Bergman, Aaronson, Ahmedzai, Kaasa, & Sullivan, 1994).  
 The Edmonton Symptom Assessment System (ESAS) is a patient self-report 
measure that evaluates the patient’s perception of symptoms at the current time. It was 
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developed and validated in a palliative care setting. Symptoms are assessed via nine 
questions that are rated on a visual analogue scale that ranges from zero to 100, with 
100 as the most severe rating. Validation testing of this scale has shown the Cronbach 
alpha coefficient for this scale to be 0.79 (Chang, Hwang, & Feuerman, 2000). Despite 
the practicality of the scale in the clinical setting, it has been inconsistently used in the 
literature and modified many times (Richardson & Jones, 2009). 
Summary 
 A variety of scales have been used from Likert type scales to visual analog 
scales like the ESAS. Although the visual analog type scale may be easier for patients 
to use (less patient burden) the efficacy of the scale is difficult to determine due to the 
fact that many researchers modify the scale from study to study. The SDS is the most 
popular symptom measurement tool in a lung cancer population. It is an effective scale 
because it measures the frequency of the symptom as well as the distress the symptom 
causes, both important clinical factors.  
Psychological Symptoms in Lung Cancer 
Compared to 14 other types of cancer, lung cancer patients report the highest 
amount of psychological distress (43%) (Zabora, et al., 2001). Depression and anxiety 
are the two most common types of psychological symptoms diagnosed in a cancer 
population (Maguire, et al., 1974) and the two variables are commonly studied together 
in an advanced cancer population (Delgado-Guay, et al., 2009; Vignaroli et al., 2006). 
Some studies suggest that depression and anxiety are underdiagnosed in an advanced 
cancer setting and that this cause a significant amount of stress for both patients and 
caregivers (Delgado-Guay, et al., 2009). The prevalence of depression and anxiety has 
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been estimated at 25% of the advanced cancer population (Salvo et al., 2011). 
However, inconsistency in the literature as well as clinician debate on how to best 
measure mental health problems in an advanced cancer population remains a problem 
(Hotopf, et al., 2002; Pasquini & Biondi, 2007). A wide variation in assessment methods, 
diagnosis criteria, and time of measurement has been attributed to the wide range of 
prevalence of depression and anxiety in an advanced cancer population (Delgado-
Guay, et al., 2009; Vignaroli, et al., 2006). There are two studies that investigate 
depression as it relates to stigma in a lung cancer population. The methodological 
analysis of these articles, Cataldo et al. (2011) and Gonzalez & Jacobsen (2010) can be 
found under stigma. The articles examined in the following table (Table 6) are those that 
address general psychological distress, depression, and anxiety within the lung cancer 
population.  
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Table 6 Analysis of Methods Used to Study Psychological Symptoms in Lung Cancer 
Study Design Sample Methods Analysis Findings 
Arrieta et al., 
(2013) 
Prospective, 
longitudinal 
study 
n=82 
Mean age=58.9 
years old 
Female=58.5% 
Smokers=50% 
Stage IIIB/IV 
NSCLC 
Mexico 
HADS 
International 
Neuropsychiatric 
Interview 
EORTC QLQ-C30 
QLQ-LC13 
Medical chart 
review 
Baseline, 3 and 6 
months 
Descriptive statistics 
Independent t-tests 
Mann-Whitney U 
Chi-squared 
Spearman 
correlations 
Depression was 
associated with 
female gender 
(p=0.034), poor 
performance status 
(p=0.048) 
58% of patients had 
depressive 
symptoms 
Patients with 
depressive 
symptoms had 
poorer adherence to 
treatment (p=0.0004) 
Haun et al. 
(2014) 
Cross-sectional 
survey 
n=54 dyads (patient 
and caregiver) 
matched community 
dyads n=162) 
Patients: 
Mean age=62.3 
years old 
Medical chart 
review 
Functional 
Assessment of 
Cancer Therapy-
Lung (FACT-L) 
Two-tailed student t-
tests 
Cohen’s D 
Spearman’s 
correlations 
Independent t-test 
32.1% of patients 
and 31.4% of 
partners met criteria 
for depression 
28.9% of patients 
and 36.0% of 
partners met criteria 
for anxiety 
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Female=35% 
Partners: 
Mean age=60.8 
years old 
Female=67% 
Germany 
ECOG 
performance 
status 
Patient Health 
Questionnaire-4 
Generalized 
Anxiety Disorder 
Scale-2 
Questionnaire on 
Distress in Cancer 
Patients-Short 
Form 
Supportive Care 
Needs Survey 
ANOVA No difference in 
depression or anxiety 
between patients and 
partners 
 
Lekka et al. 
(2014) 
Cross-sectional, 
descriptive study 
n=101 
Mean age=65.49 
years old 
Male=82.2% 
Greece 
Spielberger’s 
State-Trait Anxiety 
Inventory 
Brief Pain 
Inventory 
Family Support 
Scale 
Descriptive statistics 
Independent sample 
t-tests 
ANOVA 
Pearson correlations 
Females scored 
significantly higher 
on anxiety scale 
(p<0.01) 
53% of  males 
presented with state 
anxiety symptoms 
compared to 73.3% 
of females  
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56.43% of all 
participants 
presented with state 
anxiety symptoms 
33.7% of males 
presented with trait 
anxiety symptoms 
compared to 61.1% 
of females 
38.1% of all patients 
presented with trait 
anxiety symptoms 
Lie et al. (2015) Cross-sectional, 
descriptive study 
n=969 
Advanced cancer, 
all types 
Mean age=62.18 
years old 
85% with metastatic 
disease  
Convenience 
sample 
Multi-country 
 
Chart review 
PHQ-9 
Biomarkers  
Brief Pain 
Inventory 
Cohen’s Kappa 
Chi-square 
Mann-Whitney U 
Bivariate logistical 
regression 
45.3% of patients 
identified as 
depressed 
n=197 scored in 
moderate depression 
range  
n=75 scored in 
moderate-severe 
depression range 
n=31 scored in 
severe depression 
range 
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 Depression was 
associated with 
receiving opioid-
based medications 
(p<0.001), pain 
(p<0.001), poor 
physical performance 
(p<0.001) and 
shorter survival time 
(91-270 days, 
p<0.001; 271+ days 
p=0.01) 
 
Shi, Gu, Hou & 
Hu (2015) 
Cross-sectional, 
descriptive study 
n=104 
Inpatient 
NSCLC 
Age range=31-76 
years old 
Male=76.9% 
China 
Self-rating 
Depression Scale 
Social Support 
Revalued Scale 
Visual Analog 
Scale 
T-tests 
F-tests 
Multivariate analysis 
46.1% of patients 
were diagnosed with 
depression 
Multiple factors were 
predictors of 
depression including: 
sex (p=0.000), 
disease duration 
(p=0.006), self-care 
ability (p=0.004), and 
p=0.003) 
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Kurtz, Kurtz, 
Stommel, 
Given, & Given 
(2002) 
Longitudinal 
repeated 
measures 
descriptive 
design 
n = 228 
Convenience 
sample 
Mean age=72 years 
Male=60.1% 
Advanced 
disease=54% 
Medical chart 
review and face-
to-face interviews 
Data points: 
baseline (soon 
after treatment), 
12-16 weeks, 26-
30 weeks, 1 year 
CES-D 
Descriptive statistics 
ANOVA 
Repeated measures 
ANOVA 
Bonferroni 
corrections 
The following factors 
were important 
predictors of 
depressive 
symptoms: social 
functioning 
(p<0.0001), symptom 
severity (p<0.0001), 
and radiation 
treatment (p=0.017). 
High symptom 
burden (p<0.0001) 
and restricted social 
functioning 
(p<0.0001) were 
associated with an 
increase in 
depressive 
symptoms. 
Buccheri 
(1998) 
Cross-sectional 
descriptive 
design 
n = 133 
Consecutive 
recruitment 
Mean age=65 years 
Male (n=122) 
Medical chart 
review 
All new patients 
received 
questionnaire 
Self-rating 
Depression Scale 
Descriptive statistics 
Students t-test 
Wilcoxon test 
 
Depressed patients 
survived significantly 
less than non-
depressed patients 
(p=0.048). 
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Majority at 
advanced stage 
A. Carle Hospital 
of Chest Diseases 
Hulbert-
Williams, Neal, 
Morrison, 
Hood, 
Wilkinson 
(2011) 
Longitudinal 
cohort design 
n=160 
Convenience 
sample 
Breast, colorectal, 
lung, & prostate 
cancer 
 
Data points: 
diagnosis, 3, & 6 
months 
Hospital Anxiety 
Depression Scale 
Paired and 
independent-sample 
t-tests 
ANOVA 
Mann-Whitney U 
Kruskal-Wallis 
Chi-squared 
Regression models 
67.5% of variance in 
psychosocial 
outcomes (QOL) at 6 
months can be 
explained by 
baseline clinical 
factors, demographic 
variables, and earlier 
levels of depression 
and anxiety (p<0.01). 
Hopwood & 
Stephens 
(2000) 
Longitudinal 
RCT 
Descriptive 
Secondary 
analysis 
n=987 
Data from three 
RCTs drug trials 
 
 
Data collected 
during drug study 
visits 
Hospital Anxiety 
Depression Scale 
Descriptive statistics 
Univariate Analysis 
Wilcoxon-signed 
ranks test 
Stepwise logistic 
regression 
Depression identified 
pre-treatment 
persisted in over 
50% of patients after 
initiation of treatment. 
An increased 
symptom burden was 
associated with an 
increase in 
depressive 
symptoms 
(p<0.0001) 
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Depressive 
symptoms were 
associated with 
severity of tiredness 
(p<0.0001), 
breathlessness 
(p<0.0001), cough 
(p<0.0002), general 
pain (p<0.0001), and 
chest pain 
(p<0.0006).  
The following factors 
were significantly 
associated with 
depression at 
presentation for 
treatment (p<0.0001 
for all): cell type, 
performance status, 
functional status, 
physical symptom 
burden, tiredness, 
and breathlessness.  
Liao, Liao, 
Shun, Yu, 
Yang, & Lai 
(2010) 
Cross-sectional 
descriptive 
design 
n=152 
Convenience 
sample 
Face-to-face 
Self-report 
Descriptive statistics 
ANOVA with post 
hoc comparison 
Lung cancer patients 
report a high number 
of supportive care 
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In active treatment 
of follow up 
Mean age=60.2 
years 
NSCLC=87.5% 
Location: Taiwan 
Hospital Anxiety 
Depression Scale 
Chi-square with 
Fisher’s exact test 
Logistic regression 
needs (M=43.7, 
SD=20.0). 
The top three need 
domains for patients 
were: health system 
and information 
(M=67.9, SD=27.5)), 
psychological 
(M=41.9, SD=24.4), 
and patient care and 
support (M=41.1, 
SD=23.1). 
Significant 
relationships existed 
between overall 
symptom levels and 
depression (r=0.55, 
p<0.001) and anxiety 
(r=0.42, p<0.001). 
There was no 
significant difference 
in depression and 
anxiety among 
treatment subgroups. 
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Salvo et al. 
(2011) 
Retrospective 
analysis 
n=1439 
Convenience 
sample 
Mean age = 69 
years 
Multiple cancer 
sites: Lung, breast, 
prostate, other 
Location: Odette 
Cancer Center 
Completed on 
touch screen kiosk 
or manually 
Edmonton 
Symptom 
Assessment 
System (modified) 
Hospital Anxiety 
Depression Scale 
Univariate ordinal 
logistic regression 
Odds ratio 
Pearson Chi-
squared 
Multivariate ordinal 
logistic regression 
Wald Chi-square 
55% of patients 
reported depressive 
symptoms, 65% 
reported anxiety 
symptoms. 
The following 
demographic 
variables were 
predictors of 
depression severity: 
KPS (p<0.0001), 
gender (p=0.049), 
primary cancer site 
(specifically lung 
cancer p=0.008), and 
referral to 
radiotherapy rapid 
response for spinal 
cord compression 
(p=0.007). 
Women were more 
likely to report 
depression than 
men. 
Patients with primary 
lung cancer were 
more depressed than 
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other types of cancer 
(p=0.0008). 
Nakaya et al. 
(2006) 
Longitudinal 
repeated 
measures design 
n=229 
NSCLC only 
Post resection with 
curable intent 
Majority over age 60 
Majority male 
Majority married 
Majority past or quit 
smokers 
Location: Japan 
 
 
Structured clinical 
interviews to 
diagnose 
depression 
-Profile of Mood 
States 
Cox proportional 
hazard regression 
Hazard ratio 
 
Subjects with 
depression were 
more likely to have a 
poor performance 
status 3 months post-
surgery (p=0.30). 
Depression was not 
a predictor of survival 
in lung cancer 
patients after curative 
intent resection. 
Turner, Muers, 
Haward, & 
Mulley (2007) 
Prospective 
observational 
cohort study 
two groups, over 75 
(n=49) and under 65 
(n=83) 
Convenience 
sample 
Self-report 
Data points: before 
and after treatment 
Hospital Anxiety 
Depression Scale 
Wilcoxon matched-
pairs signed-ranks 
Mann-Whitney U 
test 
Chi-squared test 
There were no 
significant 
differences in 
psychological 
distress between the 
two groups. 
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Advanced disease 
(82%/54%) 
NSCLC (86%/84%) 
Location: 
radiotherapy 
planning clinic 
There was a trend 
towards higher 
depressive and 
anxiety symptoms 
post treatment (not 
statistically 
significant). 
There were no 
significant 
differences in the 
number of concerns 
in either group before 
and after treatment. 
Montazzeri, 
Milroy, Hole, 
McEwen, & 
Gillis (1998) 
Longitudinal 
descriptive study 
n=129 
Convenience 
sample 
Outpatient 
Mean age=67.5 
Male=60% 
Early stage 
disease=78% 
Location: Scotland 
Data points: 
baseline & 3 
months 
Hospital Anxiety 
Depression Scale 
Descriptive statistics 
Wilcoxon matched-
pairs signed-ranked 
tests 
Mann-Whitney U 
test 
Kruskal-Wallis one 
way ANOVA 
At baseline, most 
patients had normal 
depression (84%) 
and anxiety (77%) 
scores. 
Patients with 
borderline 
depression/anxiety 
scores at baseline 
were double at follow 
up (depression: 11% 
to 22%; anxiety: 6% 
to 11%). 
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There was a 
statistically significant 
difference between 
baseline and follow 
up depression scores 
(p=0.0002) but  not 
anxiety scores 
(p=0.64).  
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The literature suggests that depression and anxiety are ongoing problems in the 
lung cancer population. There is, however, conflicting published evidence on whether 
depression or depression symptoms predicts survival in lung cancer patients. Buccheri 
(1998) found that depression was correlated with shorter survival while Nakaya et al. 
(2006) found that depression was not correlated with shorter survival times. A variety of 
factors, including clinical and demographic factors, have been investigated to determine 
what may contribute to depression in lung cancer (Hulbert-Williams, Neal, Morrison, 
Hood, & Wilkinson, 2011; Kurtz, et al., 2002; Salvo, et al., 2011). Studies that examine 
anxiety in this population are more limited. Psychosocial factors, such as social support, 
have not been adequately addressed. The relationship between stigma and depression 
in lung cancer has been investigated and was presented in a previous section of this 
paper.  
Studies identified in the literature review are descriptive in nature. There are a wide 
variety of designs used to gather data, including descriptive data gathered during a 
randomized control trial. Most of the studies sought to identify what types of patient 
factors contributed to depressive symptomology or psychological distress in lung cancer 
patients. Although the majority of studies only recruited lung cancer patients, there are a 
few comparison studies with other cancer sites (breast, prostate, colorectal). Sample 
sizes for these studies are large although the majority of participants have NSCLC, are 
near or over age 65, and have advanced disease. Descriptive statistics reveal that most 
studies have an equal number of male and female participants.  
There are currently no known qualitative studies that examine psychological 
distress in a lung cancer population. 
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Summary 
 Based on this literature review, the role of stigma and other psychosocial factors 
that may be related to depression and anxiety in lung cancer patients warrants further 
investigation. The impact of psychological symptoms on physical symptoms in patients 
with lung cancer should also be explored.  
Psychological Symptoms in Lung Cancer: Measurement Tools 
 Tools that have been used to study depression and anxiety symptomology in the 
lung cancer patient population are presented in the following table (Table 7). 
Table 7 Measures and Scales to Study Psychological Symptoms in Lung Cancer 
Instrument Concept Validity Reliability 
CES-D Depression Construct/concurrent 0.85 – 0.92 
Self-Rating 
Depression Scale 
Depression Construct 0.79 – 0.81 
Hospital Anxiety 
Depression Scale 
(HADS) 
Depression and 
Anxiety 
Construct  0.85 – 0.89 
  
Depressive symptomology can be measured with the Center for Epidemiological 
Studies Depression Scale (CES-D). There are 20 items on this survey with each 
question rated on a Likert type scale from zero to three (0 = rarely/none of the time to 3 
= almost all the time). Items are added for a summed scale score. In general, a cut-off 
score of 16 is used to indicate a depressed mood in a patient, however, this can vary by 
population (Penninx et al., 1998). The CES-D has been previously validated in the 
literature (Radloff, 1977; R. Roberts & Verson, 1983). In the original validation study, the 
Cronbach alpha was 0.85 in the general population sample and 0.90 in the patient 
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population sample. Content validity was based on the clinical relevance of symptoms 
assessed on the scale (Radloff, 1977). 
The Self-Rating Depression Scale was originally developed with an inpatient 
population and subsequently validated in an outpatient population as well. The scale 
consists of 20 categorical items that cover pervasive effect, psychological equivalents, 
and physiological concomitants. Half of the items are worded symptomatically positive 
and half symptomatically negative. The survey is scored by assigning a number, one 
through four (1 = a little of the time, 2 = some of the time, 3 = a good part of the time, or 
4 = most of the time), to each item.  The highest possible score for this scale is 80 and a 
higher score indicate a more depressed patient (Zung, 1965). In an outpatient 
population consisting of 1,173 patients, the Cronbach alpha was 0.79 (Knight, Waal-
Maaning, & Spears, 1983). 
The most commonly used scale to measure depression and anxiety 
symptomology in a lung cancer population is the Hospital Anxiety Depression Scale 
(HADS). The survey was originally developed in patients with a concurrent physical 
illness.  The scale contains 14 items with two subscales, one for depressive symptoms 
and one for anxiety symptoms. Questions are rated on a four-point Likert scale. The 
instrument is summed with a higher score equating higher depressive or anxiety 
symptoms. The maximum score for this scale is 21. A score of 11 or greater represents 
a significant case of psychological morbidity (Zigmond, 1983). Both depression (r=0.60 
to 0.30, p<0.02) and anxiety (r=0.76 to 0.41) subscale questions were correlated. In the 
original sample, there were 1% false positives and 1% false negatives for the 
depression subscale and 1% false negatives and 5% false positive for the anxiety 
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subscale (Zigmond, 1983). In a large cancer population, the Cronbach alpha for the 
anxiety subscale was 0.83 and it was 0.79 for the depression subscale (Smith et al., 
2002). 
Summary 
 The most commonly used tool to study depression and anxiety in this population 
is the HADS. Because it measures both anxiety and depression within one 
measurement tool, it may be a good choice in a lung cancer population to minimize 
subject burden. The CES-D, however, has been used widely outside of the lung cancer 
literature. Selecting this scale may make it easier to compare results from a lung cancer 
population to other cancer populations. Unfortunately this measurement tool does not 
address anxiety. The HADS may be the more appropriate choice at this time due to the 
fact that anxiety has not been as widely studied as depression in lung cancer.     
Social Support in Lung Cancer 
 Social support can come in various forms. Emotional social support is the verbal 
and non-verbal communication of caring or concern offered by others to an ill individual. 
Emotional support has the ability to help provide some purpose or meaning to the 
illness experience through the expression of feelings (Helgeson & Cohen, 1996). This 
type of support often takes the form of empathy and reassurance (Helgeson & Cohen, 
1996). Informational social support provides patients a way to manage their illness 
through information that can be used to guide decisions. It can give patients a sense of 
control over their illness. Informational support helps patients to understand their 
diagnosis, the possible risk factors that contributed to the disease, as well as treatment 
and symptom management (Helgeson & Cohen, 1996). Instrumental social supports are 
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concrete goods or services. This can include money/finances, transportation, or help 
with commonplace activities like ADLs or running errands. Instrumental supports are 
tangible (Helgeson & Cohen, 1996).   
 Although the research has identified the importance of social support after a 
cancer diagnosis, there is little empirical evidence that investigates social support in a 
lung cancer population. The literature review identified five papers that address social 
support in relation to some aspect of lung cancer.  There is currently no literature 
published on stigma and social support in a lung cancer population. The published 
literature regarding social support in lung cancer is summarized in Table 8.  
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Table 8: Analysis of Methods Used to Study Social Support in Lung Cancer  
Study Design Sample Methods Analysis Findings 
Lekka et al. 
(2014) 
Cross-sectional, 
descriptive study 
n=84 
Mean age=65.49 
years old 
Male=82.2% 
Greece 
Spielberger’s 
State-Trait Anxiety 
Inventory 
Brief Pain 
Inventory 
Family Support 
Scale 
Descriptive 
statistics 
Independent 
sample t-tests 
ANOVA 
Pearson 
correlations 
Females had lower 
scores than males in 
family support (p<0.01) 
 
Family support was 
negatively correlated with 
pain severity (p<0.05), 
pain interference 
(p=0.022), state anxiety 
(p<0.001) and trait 
anxiety (p<0.001) 
 
Family support explained 
16.1% of variance in 
anxiety (R square 
change: 0.161, F: 15.72, 
B:0.129, P<0.01) 
Luszcynska, 
Pawlowska, 
Cieslak, Knoll 
& Scholz (2013) 
Systematic 
review 
n=2759 patients 
n=14 studies 
 
Range: 1990-2011 
Databases used: 
PsychINFO, 
PsychArticles, 
Health Source: 
Nursing/Academic 
Addition, Medline, 
ScienceDirect 
QOL was coded 
into 4 categories: 
physical, 
emotional, social, 
functional 
Three types of support 
identified: support from 
family and friends, from 
healthcare personnel, any 
available source 
53% of studies showed 
significant correlations 
between QOL and 
support from family and 
friends 
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Key terms: lung 
cancer, social 
support, QOL 
Initially retrieved: 
721 studies 
 
67% of studies shows 
significant correlations 
between QOL and 
support from healthcare 
personnel 
25% showed significant 
correlations between 
QOL and social support 
from other sources 
Shi, Gu, Hou & 
Hu (2014) 
Cross-sectional, 
descriptive study 
n=104 
Inpatient 
NSCLC 
Age range=31-76 
years old 
Male=76.9% 
China 
Self-rating 
Depression Scale 
Social Support 
Revalued Scale 
Visual Analog 
Scale 
T-tests 
F-tests 
Multivariate 
analysis 
30.8% reported higher 
levels of social support 
Social support was a 
predictor of self-reported 
depression in patients 
with lung cancer 
(p=0.002) 
Henoch, 
Bergman, 
Gustafsson, 
Gaston-
Johansson & 
Danielson 
(2007) 
Descriptive, 
longitudinal 
study 
n=105 
Median age=69 
years old 
NSCLC=72% 
MOS SSS 
QOL 
Spearman rank 
correlations 
Univariate 
stepwise 
regression 
Social support was 
positively correlated with 
overall QOL at several 
time points (baseline: 
0.31, p<0.05; six months: 
0.41, p<0.05; nine 
months: 0.36, p<0.05) 
 
   
 
71 
 
 Metastatic 
disease=50% 
All terminally ill, 
pursuing no 
treatment  
Social support predicted 
overall QOL at six months 
(p=0.036) and nine 
months (p=0.021) 
 
 
 
Walker, Zona & 
Fisher (2005) 
 
Cross-sectional, 
descriptive study 
n=119 
Mean age=59.1 
years old 
Post-surgical lung 
cancer patients 
Stage I or II  
White=84% 
Female=59% 
Social Support 
Inventory 
Zero order 
correlations 
First-order partial 
correlations 
Structural 
Equation Modeling 
Less adaptive coping 
methods (r=0.351, 
p<0.01) and directive 
instrumental social 
support (r=0.332, p<0.01) 
were positively correlated 
with more depressive 
symptoms 
 
There was no relationship 
between non directive 
social support and 
depressive symptoms 
 
Ell, Nishmoto, 
Mediansky, 
Mantell & 
Hamovitch 
(1991) 
Prospective, 
descriptive 
cohort study 
n=294 
Consecutive 
recruitment 
Mean age=61 
year old 
White=83% 
Record review 
Cancer registries 
Structured 
interviews 
Univariate analysis Non-survivors had less 
social integrations than 
survivors (t=2.21, p<0.01) 
 
Non-survivors reported 
more emotional support 
than survivors (t=2.54, 
p<0.01) 
In both survivors and non-
survivors psychological 
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Female=78% 
Lung 
cancer=17% 
 
distress was negatively 
correlated with emotional 
support and social 
integration (range from -
0.18 to 0.37, no p value 
given) 
 
In lung cancer patents, 
social support was not a 
statistically significant 
factor for survival 
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Summary 
 Research that examines social support in a lung cancer population is limited. To 
date, there are no studies that examine the affect that lung cancer related stigma may 
have on patient perceptions of social support. It is also unclear at this time if lung cancer 
patients feel their social support needs are met. At this time, all published studies only 
address social support in lung cancer from a quantitative perspective. 
Social Support in Lung Cancer: Measurement Tools 
 Several quantitative measurement tools have been used to assess social support 
within a lung cancer population as depicted below (Table 9). Pertinent validation 
information on these measures is presented in the following table.  
Table 9 Measures and Scales to Study Social Support in Lung Cancer 
Instrument Concept Validity Reliability 
Social Support 
Inventory (SSI) 
Social Support Construct 0.76 – 0.88 
Social Support 
Survey (MOS SSS) 
Social Support Construct 0.97 
Supportive Care 
Needs Survey 
(SCNS) 
Support Care 
Needs 
Construct 0.87 
  
The SSI is a tool used to measure reported social support. Possible responses 
for each item range from one to five and a composite score reflects the mean of the 
individual items. This 27-item scale has been used in several other populations 
including HIV, diabetes, systemic lupus erythematosus, and cancer (Fisher, LaGreca, 
Greco, Arfken, & Schneiderman, 1997; Scott, Fisher, & Hong, 1998; Walker, Larsen, 
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Zona, Govindan, & Fisher, 2004). Within the scale are four subscales that assess both 
directive and nondirective support. The four subscales are: 1) directive emotional, 2) 
directive instrumental, 3) nondirective emotional, and 4) nondirective instrumental. In 
the study by Walker, Zona, & Fisher (2005), the Cronbach alpha coefficient for the 
subscales ranged from 0.76 to 0.88.  
 The MOS SSS is a multidimensional self-report questionnaire that measure 
social support validated in a sample of 2987 adults as part of a larger study. The final 
product was a 19-item survey that measures functional support. After factor analysis, 
four subscales emerged. The subscales are tangible support, affectionate support, 
positive social interaction, and emotional/informational support. The Cronbach alpha for 
each subscale was 0.92, 0.91, 0.94, and 0.96 respectively. The Cronbach alpha for the 
total scale was 0.97 (Sherbourne & Stewart, 1991). 
 The SCNS is a 34-item survey that has previously been validated in the literature 
(Boyes, Girgis, & Lecathelinais, 2009). Questions are answered on a divided Likert 
scale. There is the option to choose no need for a particular item (1=not applicable or 
2=satisfied) or some need for a particular item (3=low need, 4=moderate need, and 
5=high need). The SCNS measure four domains related to supportive care needs, 
which are health system and information needs, such as talking with someone who 
have been through a similar experience, physical and daily living needs, such as not 
feeling well, patient care and support needs, such as a member of the healthcare team 
caring for the patients needs, and psychological needs, such as fear of recurrent 
disease. The Cronbach alpha coefficient for all four scales for the sample of lung cancer 
patients was 0.87 (Sanders, et al., 2010). 
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Summary 
 Both the SSS and the SCNS measure support in a multi-dimensional way. The 
SCNS, however, is more focused on supportive care needs rather than social support. 
The SSI has been extensively used in other populations.  
Advantages and Disadvantages of Methods Used in the Literature 
 The following section will address the advantages and disadvantages of the 
methodological approaches found in the literature. Additionally, the strengths and 
weaknesses of each type of methodology will be discussed. The following areas will be 
addressed: 1) design, 2) sample, and 3) instrument options.  
Many designs have been used to study the following key variables in lung cancer: 1) 
stigma, 2) social support, 3) psychological distress, and 4) symptoms/symptom burden. 
Designs include cross-sectional, longitudinal, as well as data collected randomized 
controlled trials. Both prospective and retrospective designs are found within the 
literature. Furthermore, both quantitative and qualitative methodological approaches 
have been used to study these variables of interest.  
Cross-sectional designs have been used to investigate stigma, symptoms, and 
social support associated with lung cancer. Some of the main advantages to using 
cross-sectional studies are that they are time-saving, economical, and practical (Polit & 
Beck, 2004). Oftentimes, cross-sectional studies have a low attrition rate due to how 
data is collected. A major strength of this type of design is all data can be collected 
within one visit. A cross-sectional design may be preferable in a lung cancer population 
because of the often quick decline and short life expectancy of lung cancer patients. 
This is true even for newly diagnosed lung cancer patients. High mortality within this 
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population can contribute to higher attrition rates if there are several time points for data 
collection. Furthermore, cross-sectional studies are less of a time burden on patients 
who may prefer to spend their time focused on other things, like preferred activities or 
time spent with family. 
A cross-sectional design is an appropriate way to collect descriptive data when the 
research question does not involve change over time. This type of design eliminates the 
pre/posttest effect and test/rest test subject bias. One weakness, however, is that a 
cross-sectional designs does not allow for questions that involve time-related causation 
(Polit & Beck, 2004).   
Longitudinal data have been used to identify patterns in physical and psychological 
symptoms and severity of these symptoms in lung cancer patients. In an advanced lung 
cancer population, longitudinal data are difficult to collect because of attrition due to 
death or the time commitment from patients who are so ill. Pretest/posttest and test-
retest bias is introduced in longitudinal study designs as well as an increased subject 
burden. Because most lung cancer patients are diagnosed at advanced stage, it can be 
assumed that many of these patients will have high disease burdens and therefore 
research burden should be minimized.  
Within the reviewed studies, the majority of data were self-reported. Only one study 
diagnosed depression through structured clinician led interviews. Self-reported 
symptoms, though important, are subjective measures. This is especially problematic 
for symptom reporting: physical symptom reporting may be highly influenced by 
emotional and social distress (Koller et al., 1996). Although clinician rating of symptoms 
may be preferable, the limited data within the lung cancer population has shown that 
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nurse’s assessment of patient symptoms may not be accurate (Broberger, et al., 
2005).Self-report of variables is practical because it is low-cost and practical to 
implement in a clinical setting. It can be completed with a regularly scheduled clinic visit 
or taken home to be completed at the convenience of the patient. Quality self-report 
data can be collected through careful selection of study instruments that have been 
previously tested and validated in the literature and used within a lung cancer patient 
and caregiver population. Furthermore, patient perception of their physiological or 
psychological distress is important because that perception represents the “reality” of 
what the patient experiences.  
Several measures have been used in the literature to measure symptoms, social 
support, and psychological variables in lung cancer patients with some used more 
extensively than others. Although there is consistency with measures for 
depression/anxiety and physiological symptoms, social support has been measured in 
many ways, some with open-ended questions/self-report. Because of this there is no 
consistency across studies as to the best or even an accurate way to measure this 
variable. Qualitative data on lung cancer patients experience with physical symptoms, 
psychological symptoms, social support and QOL is noticeably absent from the current 
literature. The degree to which patients find these key concepts to be problematic are 
important pieces of knowledge to determine the extent to which these variables are 
clinically relevant.  
Summary and Synthesis of Methodological Knowledge 
 Although there are more deaths due to lung cancer than any other type of cancer 
in the United States per year, the literature remains scant on factors that may influence 
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the lung cancer experience and health outcomes for patients within this population. As 
the public perception of smoking continues to become more stigmatized, the effect of 
this stigma on lung cancer patients, both smokers and non-smokers, becomes an 
important factor for clinicians to understand. Participation in previous health behaviors 
such as smoking is not a valid reason for anyone to have suboptimal care.  
At this time research to examine the effects of HRS on patients with lung cancer 
remains limited. Evidence about the perception of and access to social support in 
patients with lung cancer is scant. This is especially true when lung cancer is compared 
to other highly stigmatized diseases, such as HIV/AIDS, where disease-related stigma 
has been shown to have a negative effect on social support and patient outcomes.  
Though a considerable amount of research on physical and psychological symptoms 
in a lung cancer population has been published, studies are limited by cross-sectional 
designs and use of quantitative methods (i.e. surveys) which fail to provide a complete 
picture of the patient experience. Samples have been limited due to the majority of 
participants being age 65 and being primarily Caucasian samples. No studies utilize 
purposeful sampling to maximize participation by non-smokers or minority populations 
to detect differences between groups.    
Through the methodological approaches reviewed, the following implications are 
proposed: 
(1) There is a need to systematically research the phenomenon of internal and 
external HRS as they relate to the experience and care of patients with lung 
cancer. 
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(2) There is a need to conduct descriptive studies to clearly describe the effect of 
internal and external HRS on physical symptoms, psychological symptoms, 
social support, and QOL for lung cancer patients. 
(3) There is a need to develop an evidence base to guide future intervention studies 
regarding stigma in the lung cancer population. 
(4) There is a need to develop intervention studies to reduce the perception of 
stigma in lung cancer. 
In summary, lung cancer HRS is an important concept and needs to be investigated 
from a theoretical and evidence-based clinical viewpoint. 
 
 
 
 
 
 
 
 
 
 
  
   
 
80 
 
III. Methodology 
 
 
          The purpose of this section is to describe the methodology used in the 
dissertation study. This section will include research design, research setting, sample 
and sampling plan, data collection methods, and data analysis procedures. 
Research Design 
 A cross-sectional design was used in this study. Stage and chemotherapy status 
was established through oral medical history or medical chart review. Internal and 
external stigma was measured with the Internal and External Stigma Scale (Phelan, 
Griffin, Jackson, et al., 2011). Physical symptoms were measured with the MD 
Anderson Symptom Inventory—Lung Cancer (MDASI-LC) (Mendoza et al., 2011). 
Psychological symptoms, depression and anxiety, was identified via the Hospital 
Anxiety and Depression Scale (HADS) (Smith, et al., 2002; Zigmond, 1983). 
Psychological distress (Hoffman, Zevon, D'Arrigo, & Cecchini, 2004) was measured 
using a one item scale. Social support was examined with the Medical Outcomes 
Survey—Social Support Survey (MOS SSS) (Sherbourne & Stewart, 1991) and the 
Social Constraints Scale (Lepore, 2001; Lepore & Ituarte, 1999). QOL was measured 
using the Linear Analog Self-Assessment Scale (LASA) (Locke et al., 2007).   
Research Setting 
 The study was conducted in the outpatient clinics at the Vanderbilt Ingram 
Cancer Center located in Nashville, TN. The number of new NSCLC patients seen at 
the Vanderbilt Ingram Cancer Center in a year is 314 with 131 of those having Stage IV 
disease. Of the 32 new cases of SCLC seen, 15 have stage IV disease (J. Roberts, 
2012) and these numbers do not include patients who come to Vanderbilt after 
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completing some type of therapy elsewhere. Or those who have progression of disease 
while at Vanderbilt (J. Roberts, 2012). Patients were also identified with the assistance 
of LUNGevity and the Lung Cancer Alliance. PI contact information was provided via 
website and mail to members.  
Sample and Sampling Plan 
Size of Sample 
 Stigma in patients with lung cancer remains a relatively understudied 
phenomenon. LaConte et al. (2008) found that approximately 30% of patients with lung 
cancer experienced feelings of stigma. For this study a convenience sample of 62 
participants was recruited from a combination of patients at the Vanderbilt Ingram 
Cancer Center and from LUNGevity and the Lung Cancer Alliance.  
Criteria of Sample Selection 
 The targeted population was adult patients with lung cancer. Inclusion criteria 
included: (1) 18 years old; (2) received chemotherapy for lung cancer; (3) speaks 
English. Exclusion criteria include the following; (1) have not received chemotherapy for 
lung cancer; (2) documentation of cognitive impairment that would preclude the ability to 
provide informed consent; (3) have any other active cancer, (4) enrolled in hospice.   
 The underlying principles for the proposed exclusion criteria were as follows: (1) 
Patients who receive chemotherapy have an advanced stage of lung cancer and 
therefore have a higher degree of symptom burden than those with early stage disease 
(Degner & Sloan, 1995). Patients with curable disease may experience different 
treatment strategies from those with non-curable disease and therefore have different 
physical and emotional responses. These varying responses may be potential 
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confounding variables in the proposed research study. (2) Patients with documented 
cognitive impairments may not be able to fully understand informed consent and 
excluding these patients will help avoid any confounding effects on the self-reported 
subjective measures in the proposed research study. (3) Patients with other active 
cancers may experience different treatment regimens than those who only have lung 
cancer. Patients with other active diseases may therefore experience different physical 
or emotional responses to treatment and the varying responses may be potential 
confounding variables in the proposed research study. (4) Patients enrolled in hospice 
have different goals of care and receive different treatment interventions that may 
change the number or perception of physical or psychological symptoms.  
 
Methods for Subject Recruitment  
 Patients were identified by the PI or physician by screening patients at the 
Vanderbilt-Ingram Cancer Center (VICC). Patients were recruited via the following 
steps: (1) The PI visited with medical oncologist at VICC and told them about the 
purpose and procedures of the study. (2) The medical oncologist told potential 
participants about the study. (3) The PI screened and recruited participants who 
expressed interest in the study using the eligibility criteria form.  
 Additional patient subjects were recruited via the internet through LUNGevity, 
and the Lung Cancer Alliance. Study measures were loaded onto Red Cap, an online 
program, and contact information to the PI was placed on relevant websites.  
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Strategies to Ensure Human Subject Protection 
 Approval from the Institutional Review Board (IRB) at Vanderbilt University and 
the Scientific Review Committee (SRC) at the VICC were obtained prior to recruitment. 
Participation was open to all patients who had received chemotherapy to treat lung 
cancer and there was no exclusions based on gender, race, or ethnicity. No risks were 
anticipated for participants other than time inconvenience. Participants could withdraw 
for any reason by informing the PI of their desire to do so.  
 Compliance to study protocol was maintained by the PI through meetings with 
the PI’s advisor, Dr. Sheila Ridner. Random selections of participant data were 
examined and the PI reported any study related issues to the advisor which included 
difficulty with recruitment, retention, data collection, or data entry or any other problem.  
Local Participants  
The PI obtained informed consent of all participants prior to data collection. The 
following steps were used: (1) The PI explained the study to potential participants. (2) 
Potential participants were provided with a hard copy of the consent to read and review. 
(3) The PI provided all potential participants with the opportunity to ask questions during 
and after their review of the informed consent. (4) The PI answered all questions about 
the study. (5) Potential participants agreed to be in the study and signed the informed 
consent with the PI serving as witness. To ensure confidentiality, informed consent was 
obtained in a private location. 
Distance Participants 
 Participants who do not receive care at VICC contacted the PI via a toll-free 
study number or by email. (1) The PI explained the study to potential participants. (2) 
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The patient was given the opportunity to answer questions and the PI answered all 
questions. (3) Eligible patients who participated were sent a link to a REDCap survey 
via a designated email address. (4) Informed consent was on the REDCap survey so no 
hard copy of the consent will be maintained by the PI.  
 To maintain participant confidentiality, the PI contacted, screened, obtained 
informed consent, and conducted data collection in a private area. All data files were 
saved in hard copy format and password protected electronic format. Hard copies of 
data are stored in a locked file cabinet. All data collected was coded and given a 
participant number so that the participant’s name and other identifiable information was 
not associated with the data. The PI, the PI’s advisor, and the statistician (member of 
dissertation committee) had access to the electronic data files. Only the PI and the PI’s 
advisor had access to the hard copy data. The hard copies of the data will be stored in a 
locked cabinet and the PI and the PI’s advisor will maintain the electronic data in the 
password-protected database.  
 
Data Collection Methods 
Procedures 
Local Participants 
The researcher contacted subjects using a script and possible participants were 
screened using an eligibility form. Once an exclusion criterion was met, no other 
information was gathered. Eligible subjects were given the Short Portable Mental Status 
Questionnaire. If the patient was eligible he or she was provided an informed consent 
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and interested participants signed the consent. Patients then answered the study 
measures. All data collected from participants will be locked and stored in a safe place. 
Distance Participants 
 Distance participants were screened verbally over the phone to determine 
eligibility. The PI administered the Short Portable Mental Status Questionnaire over the 
phone to eligible patients. If the patient passed the screening, an email with a REDCap 
link was sent to the participant. One week later a reminder email was sent if he or she 
has not completed the study measures.  
 
Instruments 
 The instruments used to measure stigma, physical symptoms, psychological 
symptoms, social support, and QOL are listed below. The content, reliability, and validity 
of the selected instruments are discussed.  
Stigma This scale consisted of 6 questions and was adapted from previously 
used stigma and blame scales to measure general cancer stigma, self-blame (internal 
stigma) and perceived blame (external stigma) in veteran male colorectal cancer 
patients. Two general cancer stigma items frequently endorsed by cancer patients were 
adapted from the Experiences of Rejection and Stigma Measure (Fife & Wright, 2000). 
Two additional general cancer stigma items were selected from other stigma literature 
(Link, Struening, Rahav, Phelan, & Nuttbrock, 1997; Phelan, Griffin, Hellerstedt, et al., 
2011; Szmukler et al., 1996). One item was selected to measure self-blame (internal 
stigma) and one item was selected to measure the perception of blame from others 
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(external stigma). Both items were adapted from the Experiences of Rejection and 
Stigma Measure (Fife & Wright, 2000).  
In this dissertation study, items on this scale were individually scored and 
individually correlated with other study measures. Because the scale was not summed 
no Cronbach’s alpha was generated for this study measure.  
 M.D. Anderson Symptom Inventory—Lung Cancer. The MDASI-LC consisted of 
the 13 core symptom items found on the original MDASI measurement instrument as 
well as six core MDASI symptom interference items and three lung cancer specific 
questions (coughing, constipation, and sore throat) (Mendoza, et al., 2011). Scores for 
both symptom severity and symptom interference were calculated although symptom 
interference was not part of this dissertation study. The Cronbach’s alpha for the 
symptom severity portion of the MDASI-LC in this study was 0.92 and for the symptom 
interference was 0.93.  
 Psychological Distress. Psychological distress was measured with the one item 
Distress Thermometer (DT) developed by the National Comprehensive Cancer Network 
(NCCN). Patients were asked to rate their distress on a scale from 0 to 10. 
Hospital Anxiety and Depression Scale. The Hospital Anxiety and Depression 
Scale (HADS) is a self-report instrument that was developed to measure symptoms of 
depression and anxiety in the non-psychiatric hospitalized population (Zigmond, 1983). 
In this study depression and anxiety subscales were used as separate variables in the 
statistical analysis and the total scale score for the HADS was not used in any statistical 
analysis. The Cronbach’s alpha for the depression subscale was 0.83 and for the 
anxiety subscale was 0.86. 
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Quality of Life Scale (Linear Analog Self-Assessment LASA). The LASA is a 5-
item, psychometrically validated, linear analog scale. In this study individual items on 
this instrument were correlated with other study measures.  
Social Support  
 Social support was measured by two instruments.  
Medical Outcomes Survey—Social Support Scale. The MOS SSS is a 
multidimensional self-report questionnaire that measure social support validated in a 
sample of 2987 adults as part of a larger study (Sherbourne & Stewart, 1991). The 
summed score from this scale was used in statistical analysis. The Cronbach’s alpha for 
this measure in this dissertation study was 0.95.  
Social Constraints Scale. The Social Constraints Scale consists of 15 items that 
measures social constraints due to disclosure of a cancer diagnosis (Lepore, 2001; 
Lepore & Ituarte, 1999). This scale specifically measures behaviors that the spouse or 
partner of a patient may participate in after a cancer diagnosis, such as willingness to 
discuss the diagnosis, and how often the spouse engages in these behaviors. In this 
study, the summed score was used in statistical analysis. The Cronbach’s alpha for this 
instrument in this study was 0.94.  
 Demographic and Background Information Form. This form included age, 
gender, race, level of education, marital status, employment status, current medications, 
smoking history, and other pertinent risk factor exposure information. Information for this 
form was collected via patient or nurse interview. 
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 Lung Cancer Disease and Treatment Information Form. This form included date 
of diagnosis and type of lung cancer, TNM stage, and tumor type. It also included types 
and dates of treatments and treatment toxicity information.  
Table 10 Data Resources and Data Collection Methods 
Concepts 
Measured 
Measurement 
Variables 
Measurement 
Instruments 
Data Collection 
Methods 
Stigma Stigma Stigma and Self-Blame 
Scale 
Subject Self-
report 
Symptoms Physical Symptoms MD Anderson Symptom 
Inventory-Lung Cancer 
(MDASI-LC) 
Subject Self-
report 
Psychological 
Symptoms 
Hospital Anxiety and 
Depression Scale 
(HADS) 
Subject Self-
report 
Psychological 
Distress 
Psychological Distress NCCN Distress 
Thermometer 
Subject Self-
report 
Social Support Social Support Medical Outcomes 
Survey Social Support 
Survey (MOS SSS) 
Subject Self-
report 
Social Constraints Scale Subject Self-
report 
Quality of Life Quality of Life Linear Analog Self-
Assessment Scale 
(LASA) 
Subject Self-
report 
 Demographic Data Demographic and 
Background Information 
Form 
Researcher 
Interview 
Cancer Treatment 
Data 
Lung Cancer Disease & 
Treatment Information 
Form 
Researcher 
Medical Chart 
Review 
 
Data Analysis 
 The PI entered the data into SPSS version 23. Data validation and data cleaning 
was used to check for outliers, wild codes, and internal data consistency (Polit & Beck, 
2004). To address missing data, the PI determined the distribution and pattern of the 
missing data and a decision was made based on the extent and patterns of the missing 
values. Cases which contained no or minimal data were eliminated and one variable 
(function) was eliminated due to paucity of collected data and interpretation difficulties 
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(Polit & Beck, 2004). Decisions regarding missing data were made after discussions 
with the statistician.  
 Descriptive statistics were used to describe the sample and to check the 
distribution of continuous variables, such as demographic information and self-report 
measure scores. Mean and standard deviation were used to describe participant age. 
All other continuous variables were skewed and median and interquartile range were 
used to describe these variables. Categorical and ordinal data were summarized using 
frequency distributions. In addition, ordinal scale data summaries included median and 
inter-quartile range when appropriate. Data were then analyzed according to the 
proposed aims of the study.  
1. What are the associations between internal and external HRS and (a) symptoms, (b) 
social support, and (c) QOL in patients with advanced lung cancer? 
Data Analysis Methods: Spearman rho correlations were used to determine 
relationships between stigma and subsequent variables.  
2. What are the associations between physical symptoms and (a) social support and (b) 
QOL in patients with advanced lung cancer?  
Data Analysis Methods: Spearman correlations were used to determine relationships 
between physical symptoms and subsequent variables.  
3. What are the associations between psychological symptoms and (a) social support 
and (b) QOL in patients with advanced lung cancer?  
Data Analysis Methods: Spearman rho correlations was then used to determine 
relationships between psychological symptoms and subsequent variables.  
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CHAPTER IV 
 
FINDINGS 
 
 Findings of the study based on statistical analysis are found in this chapter. In the 
first section, the study participants and study measure scores are described. In the 
second section the results of the study aims are presented. 
 
Sample Characteristics 
 In this section the demographic characteristics, health behaviors characteristics, 
and sample scores will be described. 
 A convenience sample of 67 adult patients with lung cancer were recruited from 
the Vanderbilt-Ingram Cancer Center as well as via nation-wide e-mail and paper mail 
announcements through the Lung Cancer Alliance and the LUNGevity Foundation. Data 
were collected from November 2012 through August 2014. All participants received 
some type of chemotherapy as treatment for their disease.  
Demographic Characteristics 
 Demographic data were collected (see Table 11). Patients ranged in age from 
42-83 years with a mean age of 64.45 (8.69) years. The majority were female (59.7%), 
white (87.1%), and married (77.4%). Most participants in this study were highly 
educated with 21.0% completing some college and 43.5% completing college or a 
higher degree. Approximately 40% of patients lived in a rural setting (38.7%).  
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Table 11 Demographics of Study Sample (n=62) 
Characteristic  Mean Standard Deviation 
Age (years) 64.45 8.69 
Characteristic Frequency (%) 
Gender Male 24 (38.7) 
Female 37 (59.7) 
Race American 
Indian/Alaskan 
Native 
2 (3.2) 
Asian 1 (1.6) 
Black or African 
American 
4 (6.5) 
White 54 (87.1) 
Education  Some high school 4 (6.5) 
High school 
graduate 
18 (29.0) 
Some college 13 (21.0) 
College degree or 
higher 
27 (43.5) 
Marital Status Single 5 (8.1) 
Single, living with 
partner 
1 (1.6) 
Married 48 (77.4) 
Widowed 7 (11.3) 
Employment Full time 14 (22.6) 
Part time 5 (8.1) 
Homemaker 1 (1.6) 
Retired 30 (48.4) 
Unemployed 3 (4.8) 
 Other 8 (12.9) 
Residence Urban 34 (54.8) 
Rural  24 (38.7) 
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Health Behavior Characteristics 
In this study, smoking was defined as smoking more than 100 cigarettes in a 
lifetime. Smoking data are presented in Table 12.  
The majority of patients reported a smoking history (66.1%). Of those patients 
who report a history of smoking, however, 90.2% reported they had stopped smoking 
prior to the study assessment. Within those who report a smoking history, 59.7% 
reported smoking cigarettes and 6.5% reported smoking marijuana.  
Of those who reported a history of smoking, the number of years smoked ranged 
from 2-52 years. Patients reported a history of using 1-60 cigarettes per day with a 
mean of 27.1 (14.5) cigarettes per day. The mean number of years ago that patients in 
this study stopped smoking ranged from 1-47 years. Only seven patients in this study 
reported they were currently smoking. 
Table 12 Health Behavior Characteristics (n=62) 
Characteristics Yes No 
 Frequency (%)  Frequency (%) 
Have you ever smoked? 41 (66.1) 19 (30.6) 
Have you quit smoking  37 (59.7) 7 (11.3) 
Do you drink alcohol? 20 (32.3) 41 (66.1) 
Have you quit using 
alcohol? 
3 (4.8) 12 (19.4) 
Characteristic IQR Median Min Max 
Smoking History (years) 15-40 27.50 2 52 
Quit Smoking (years ago) 4-29 15.50 1 47 
Number of Cigarettes  
(per day—past)* 
20-40 22.00 1 60 
Number of Cigarettes  
(per day—current)*  
n/a 10.00 3 12 
 
*n=3 
 
 
 
   
 
93 
 
Descriptive Summaries of Scores from the Study Instruments 
 Scores on study instruments are summarized in Table 14. Stigma only data are 
in Table 13.  
 STIGMA. Higher scores indicate a higher degree of perceived stigma. In this 
study, 69.4% of patients reported they did not feel that other people avoided them 
because of a diagnosis of lung cancer. When patients were asked if they felt others 
were awkward or tense around them because of lung cancer, 46.8% reported this was 
not at all true and 29.0% reported this was a little true.  Patients were asked if they felt 
that there is a stigma associated with lung cancer and 46.8% of patients said this was 
not at all true while 33.9% of patients said this was completely true. Patients were asked 
if they felt that people thought less of someone with lung cancer and 56.5% reported 
this was not at all true. In this study sample only 11.3% of patients reported it was 
completely true that they were to blame for their disease compared to 58.1% feel that is 
not at all true. Only 14.5% of patients reported they feel it is completely true that others 
blame them for their diagnosis of lung cancer while 40.3% feel this is not at all true.   
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Table 13 Sample Scores on Stigma Scale 
 
MOS SSS. In this study, scores ranged from 2.2 to 5.0 (scale range 0 – 5). 
Higher scores indicate a patient perceives high access to social support. The patients in 
this sample displayed a median of 4.7 (IQR = 2.2-4.9). The high median score on the 
MOS SSS indicates that within this sample the majority of patients felt they had access 
to social supports. (see Table 14) 
 SCS. Lower scores on the SCS indicates a patient perceives their main caregiver 
to be more supportive (scale range 0-150). Patients in this sample displayed a median 
score of 12.0 (IQR = 4.0-39.0). The low median score on this scale show that most 
patients in this study felt their main caregiver was supportive after their diagnosis of lung 
cancer. (see Table 14) 
MDASI-LC. Higher scores indicate a higher symptom burden severity or a higher 
interference of symptoms on the patient’s feelings and function. In this sample, the 
 Not at 
all True 
N (%) 
A Little 
True 
N (%) 
Somewhat 
True 
N (%) 
Completely 
True 
N (%) 
External Stigma 
I feel that some people avoid me 
because I have lung cancer. 
43 
(69.4) 
8 (12.9) 7 (11.3) 4 (6.5) 
I feel that some people feel awkward 
and tense around me because I 
have lung cancer. 
29 
(46.8) 
18 
(29.0) 
9 (14.5) 6 (9.7) 
I feel there is a stigma that goes with 
my condition. 
29 
(46.8) 
6 (9.7) 6 (9.7) 21 (33.9) 
I feel that most people think less of a 
person who has lung cancer. 
35 
(56.5) 
10 
(16.1) 
10 (16.1) 7 (11.3) 
Internal Stigma 
I feel I am to blame for my disease. 36 
(58.1) 
8 (12.9) 11 (17.7) 7 (11.3) 
I feel other people think I am to 
blame for my disease. 
25 
(40.3) 
16 
(25.8) 
11 (17.7) 9 (14.5) 
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median score for the symptom severity scale was 1.4 (IQR = 0.5-2.7) and the median 
score for the symptom interference scale was 1.7 (IQR = 0.2-3.5), indicating the majority 
of patient’s experienced extremely mild symptom burden severity and symptom 
interference. (see Table 14) 
HADS. Higher scores on the HADS indicate more symptoms of depression or 
anxiety. On the depression subscale, scores ranged from 0 to 14.0 (median=3.0; IQR = 
2.0-7.0) and on the anxiety subscale, scores ranged from 0 to 20.0 (median=6.0; IQR = 
3.0-8.0). Data indicate most patients in this study had relatively few symptoms of 
depression or anxiety. (see Table 14) 
DISTRESS THERMOMETER. Patients were asked to rate their level of distress. 
On this scale, lower scores indicate a lower level of overall distress. The median level of 
distress was 3.0 indicating that most participants were experiencing mild to moderate 
levels of distress. (see Table 14) 
 LASA. LASA was used to examine QOL for patients in several specific domains 
and general QOL. A higher scores indicates a higher level of QOL (Physical domain, 
M=6.6; Emotional domain, median = 8.0, IQR = 5.8-10.0; Spiritual domain, median = 
9.0; IQR = 7.6-10.0; Intellectual domain, median = 8.0, IQR = 7.0-10.0; Overall domain, 
median = 8.0, IQR = 7.0-9.0). Within this sample, most participants reported a moderate 
to high degree of QOL in both specific domains and overall QOL. (see Table 14) 
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Table 14 Internal Consistency and Sample Scores on the Instruments 
Instrument (# items) N Median IQR (25, 75) Min Max Cronbach’s Alpha 
MOS SSS 62 4.7 2.2 4.9 2.2 5.0 .95 
Social Constraints 
Scale 
60 12.0 4.0 39.0 0.0 106.0 .94 
MDASI-LC 
   Severity (16) 63 1.4 0.5 2.7 0.0 7.4 .92 
   Interference (6) 62 1.2 0.2 3.5 0.0 7.5 .93 
HADS 
   Depression (7) 58 3.0 2.0 7.0 0.0 14.0 .83 
   Anxiety (7) 56 6.0 3.0 8.0 0.0 20.0 .86 
Distress 
Thermometer 
61 2.0 0.0 5.0 0.0 9.0 -- 
LASA (5) 
   Physical item (1) 62 7.0 5.0 8.0 2.0 10.0 -- 
   Emotional item (1) 62 8.0 5.8 10.0 1.0 10.0 -- 
   Spiritual item (1) 62 9.0 7.8 10.0 2.0 10.0 -- 
   Intellectual item (1) 62 8.0 7.0 10.0 2.0 10.0 -- 
   Overall item (1) 62 8.0 7.0 9.0 1.0 10.0 -- 
 
Findings Related to Study Aims 
 
Aim 1: To examine the relationship between patient perceived internal and external 
HRS, physical symptoms, psychological symptoms, social support, and QOL. 
 Correlations of external HRS with patient scores on the MDASI-LC (symptom 
severity only), HADS, distress thermometer, MOS SSS, and SCS are shown in Table 
16. None of the correlations with questions related to external HRS and the MDASI-LC 
or the HADS were statistically significant (p > 0.05). (see Table 15) 
Three of the four scale items related to external stigma showed statistically 
significant positive correlations with patient distress. Those questions include: 1) patient 
perception that others feel awkward or tense around them (rs(63) = .30, p = .018), 2) 
patient perception that there is a stigma with lung cancer (rs(63) = .26, p = .047), and 3) 
patient perception that others think less of a person with lung cancer (rs(63) = .30, p = 
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.020). As the patient perception of external stigma increased, patient distress also 
increased. (see Table 15) 
Responses to the individual external stigma questions showed negative 
correlations with the MOS SSS. As patient perception of external stigma increased 
patient reported access to social supports decreased. The strongest correlation was 
found between perceiving there is a stigma associated with lung cancer and access to 
social support (rs(62) = -.44, p < .001). (see Table 15) 
Statistically significant positive correlations were found between three individual 
questions related to external stigma and scores on the SCS. This indicates that as 
patient perception of external stigma increases the perception that the main caregiver is 
less supportive also increases or that as the perception of support from the main 
caregiver decreases the perception of external HRS increases. (see Table 15) 
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Table 15 Correlations of External HRS with Physical Symptoms, Psychological 
Symptoms and Social Support 
 Physical 
Symptoms 
Depression Anxiety Distress Social Support 
     MOS 
SSS 
SCS 
I feel that 
some people 
avoid me 
because I 
have lung 
cancer. 
-.17 
(.200) 
-.01 
(.950) 
-.05 
(.713) 
.19 
(.147) 
-.26 
(.044) 
.25 
(.055) 
I feel that 
some people 
feel awkward 
and tense 
around me 
because I 
have lung 
cancer. 
-.03 
(.831) 
.03 
(.848) 
.02 
(.883) 
.30 
(.018) 
-.35 
(.006) 
.39 
(.002) 
I feel there is 
a stigma that 
goes with my 
condition. 
-.04 
(.791) 
-.001 
(.979) 
.02 
(.918) 
.26 
(.047) 
-.43 
(.001) 
.33 
(.011) 
I feel that 
most people 
think less of a 
person who 
has lung 
cancer. 
.01 
(.915) 
-.004 
(.979) 
.06 
(.689) 
.30 
(.020) 
-.44 
(<.001) 
.36 
(.005) 
* Note: Values in cells are rs (p-value) 
 
Correlations of external HRS with QOL are shown in Table 16. Almost all 
domains of QOL showed statistically significant negative correlations with patient’s 
perceptions of external stigma. The strongest association was observed for the patient’s 
perception that some people feel awkward and tense due to a diagnosis of lung cancer 
with overall QOL (rs(63) = -.47, p < .001). As patient perception of external stigma 
increased, in general, the patient’s perception of QOL decreases, or conversely, as the 
   
 
99 
 
patient’s perception of most domains of QOL decreases, the perception of external HRS 
increased.  
Table 16 Correlations of External HRS with Domains of QOL 
 Physical 
Domain 
Emotional 
Domain 
Spiritual 
Domain 
Intellectual 
Domain 
Overall 
QOL 
I feel that some 
people avoid me 
because I have 
lung cancer. 
-.26 
(.041) 
-.21 
(.108) 
-.16 
(.210) 
-.30 
(.018) 
-.38 
(.002) 
I feel that some 
people feel 
awkward and 
tense around me 
because I have 
lung cancer. 
-.36 
(.004) 
-.40 
(.001) 
-.36 
(.003) 
-.46 
(<.001) 
-.47 
(<.001) 
I feel there is a 
stigma that goes 
with my condition. 
-.36 
(.004) 
-.29 
(.024) 
-.27 
(.033) 
-.30 
(.019) 
-.38 
(.002) 
I feel that most 
people think less 
of a person who 
has lung cancer. 
-.40 
(.001) 
-.34 
(.006) 
-.33 
(.008) 
-.39 
(.001) 
-.36 
(.004) 
* Note: Values in cells are rs (p-value) 
 
Table 17 shows the correlations of patient perception of internal stigma related to 
a lung cancer diagnosis with physical symptoms, psychological symptoms, and social 
support. No statistically significant associations of the two internal stigma items with 
physical or psychological symptoms nor with the perception of support by the main 
caregiver as measured by the SCS measurement tool were found. There was a single 
statistically significant inverse correlation between the perception that others blame the 
patient for their disease with the scores on the MOS SSS (rs(62) = -.29, p = .025) 
indicating that when a patient feels others think he or she is to blame for their disease 
they perceives less access to social supports or that when a patient perceives less 
access to social supports the perception that one is to blame for lung cancer increases.  
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Table 17 Correlations of Internal HRS with Physical Symptoms, Psychological 
Symptoms and Social Support 
 Physical 
Symptoms 
Depression Anxiety Distress Social Support 
MOS 
SSS 
SCS 
I feel I am to 
blame for my 
disease. 
-.007 
(.956) 
-.04 
(.800) 
-.26 
(.067) 
-.05 
(.732) 
.02 
(.858) 
-.15 
(.272) 
I feel other 
people think I 
am to blame 
for my 
disease. 
-.14 
(.287) 
-.12 
(.401) 
-.20 
(.164) 
.24 
(.064) 
-.29 
(.025) 
.23 
(.083) 
* Note: Values in cells are rs (p-value) 
 
The correlations of internal HRS with QOL are shown in Table 18. Blaming 
oneself for the disease showed an inverse association with scores for physical QOL    
(rs(63) = -.41, p = .001) and emotional QOL (rs(63) = -.27, p = .031). Feeling like others 
blamed the patient for lung cancer showed an inverse association with physical QOL   
(rs (63) = -.30, p = .021), intellectual QOL (rs(63) = -.26, p = .046), and overall QOL      
(rs (63) = -.31, p = .016). QOL decreased for patients as the perception of internal 
stigma related to a diagnosis of lung cancer increased or as the perception of internal 
stigma increased for patients, QOL decreased.  
Table 18 Correlations of Internal HRS with Domains of QOL 
 Physical 
Domain 
Emotional 
Domain 
Spiritual 
Domain 
Intellectual 
Domain 
Overall QOL 
I feel I am to 
blame for my 
disease. 
-.41 
(.001) 
-.27 
(.031) 
-.14 
(.269) 
-.10 
(.462) 
-.23 
(.067) 
I feel other 
people think I 
am to blame 
for my 
disease. 
-.30 
(.021) 
-.20 
(.118) 
-.21 
(.101) 
-.26 
(.046) 
-.31 
(.016) 
* Note: Values in cells are rs (p-value) 
 
   
 
101 
 
Aim 2: To examine the associations between physical symptoms and social support, 
and QOL in patients with advanced lung cancer.  
 Associations of scores on the measure of social support and QOL with reports of 
physical symptoms are shown in Table 20. No statistically significant correlations were 
found. (See Table 19) 
Table 19 Correlations of Physical Symptoms with Social Support and QOL 
 Physical Symptoms 
MOS SSS -.18 
.188 
SCS -.09 
.502 
QOL   
     Physical Domain -.13 
.334 
     Emotional Domain -.05 
.685 
     Spiritual Domain -.20 
.123 
     Intellectual Domain -.04 
.739 
     Overall QOL -.04 
.745 
* Note: Values in cells are rs (p-value) 
 
Aim 3: To examine the associations between psychological symptoms and social 
support, QOL, and function in patients with advanced lung cancer. 
 Associations of scores on the measures of social support and QOL with HADS 
depression scores are shown in Table 20. No statistically significant correlations were 
found. (See Table 20) 
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Table 20 Correlations of Social Support and QOL with HADS Depression Scores 
 HADS Depression Score 
MOS SSS -.26 
(.062) 
SCS .05 
(.707) 
QOL   
     Physical Domain -.04 
(.788) 
     Emotional Domain .09 
(.502) 
     Spiritual Domain -.12 
(.400) 
     Intellectual Domain .02 
(.886) 
     Overall QOL .02 
(.903) 
* Note: Values in cells are rs (p-value) 
 
 Associations of score on the measures of social support and QOL with HADS 
anxiety scores are shown in Table 22. No statistically significant correlations were 
found. (See Table 21). 
Table 21 Correlations of Social Support and QOL with HADS Anxiety Scores 
  HADS Anxiety Scores 
MOS SSS -.14 
(.324) 
SCS -.12 
(.420) 
QOL   
     Physical Domain .14 
(.319) 
     Emotional Domain .10 
(.465) 
     Spiritual Domain -.14 
(.318) 
     Intellectual Domain .06 
(.697) 
     Overall QOL .06 
(.689) 
* Note: Values in cells are rs (p-value) 
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 Associations of scores on the measure of distress and social support and QOL 
with distress are shown in Table 23. No statistically significant associations were found 
of scores on the MOS SSS and SCS with the distress thermometer score. Statistically 
significant inverse associations of the QOL scores with the distress score were 
observed (rs(63) = -.32, p = .013), emotional QOL  (rs(63) = -.63, p < .001), spiritual QOL 
(rs(63) = -.50, p < .001), intellectual QOL (rs(63) = -.61, p < .001), and overall QOL 
(rs(63) = -.60, p < .001). As distress increased, patient QOL decreased in all four 
domains of QOL as well as overall QOL or as QOL decreased patient distress 
increased. (See Table 22) 
Table 22 Correlations of Distress and Social Support with QOL 
 Distress Thermometer Scores 
MOS SSS -.13 
(.321) 
SCS .16 
(.239) 
QOL   
     Physical Domain -.32 
(.013) 
     Emotional Domain -.63 
(<.001) 
     Spiritual Domain -.50 
(<.001) 
     Intellectual Domain -.61 
(<.001) 
     Overall QOL -.59 
(<.001) 
* Note: Values in cells are rs (p-value) 
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CHAPTER V 
 
DISCUSSION 
 
 A discussion of study findings is presented in this chapter and outlined as 
follows: (a) critique of study design, (b) sample (c) aims, (d) study limitations and 
alternative explanations, (e) implications, and (f) recommendations for future research. 
 
Critique of Study Design and Methods 
 The following section will address the credibility, rigor and validity of the research 
design and methods used in this dissertation study. Additionally, strategies for 
minimizing weakness are identified and discussed. 
 A cross-sectional design was selected for this dissertation study. One reason this 
design was chosen was to minimize attrition by collecting all data during a single patient 
visit. Despite advances in treatment, advanced lung cancer patients continue to have a 
high mortality rate and therefore attrition can be problematic in longitudinal studies in 
this population. Additionally, a cross-sectional design limits the time burden patients 
with advanced lung cancer spend completing study instruments. This allows patients to 
spend more time with family or friends or engaged in activities they find enjoyable. By 
selecting a cross-sectional design, pre/posttest effect and test/retest subject bias was 
avoided. Finally, this study did not attempt to address changes in perception of stigma 
or other variables over time making a cross-sectional design an appropriate choice. 
However, the inability to address time-related causation is a weakness in the design 
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choice. The patients who enrolled in this study were all at various points in their 
treatment continuum. Some were just beginning chemotherapy and some had 
exhausted all traditional treatments and were enrolled in experimental drug trials. 
Stigma, physiological and psychological variables, as well as distress and social support 
may be different at different points in the treatment trajectory and study was not able to 
detect these differences. To minimize this weakness, appropriate statistical analysis 
was used and results were interpreted to represent the data as collected.  
 Self-report measures were chosen to collect data for this dissertation study. The 
limited data available in patients with lung cancer indicate that nurse assessment of 
patient symptoms may not be accurate (Broberger, et al., 2005). To ensure the quality 
of self-report data and to minimize any weakness from collecting only subjective, self-
report data in this dissertation study, instruments were carefully selected through a 
thorough review of all available instruments for all concepts measured. The PI, in 
conjunction with the dissertation chair, then selected the best available instruments 
taking into account the reliability and validity of each instrument and its previous use in 
patient with lung cancer. The patient perception of physiological and psychological 
symptoms is extremely important. Like pain, which can only be defined by the patient, 
physiological and psychological symptoms are also a patient-centered experience and 
are best measured through the perception of the individual patient. Only the individual 
patient experiences the “reality” of their own symptoms.  
 Social support is an understudied concept in patients with lung cancer. Because 
of this, there is little prior data on which to base the selection of instruments. A lack of 
previously tested social support measures is a weakness in the methods of this study. 
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Two measures of social support were chosen for this study in order to minimize this 
weakness.  
 
Summary and Synthesis of Study Design and Methods 
Although there are more deaths due to lung cancer than any other type of cancer 
in the United States per year, the literature remains scant on factors that may influence 
the lung cancer experience and health outcomes for patients within this population. As 
the public perception of smoking continues to become more stigmatized, the effect of 
this stigma on lung cancer patients, smoking and non-smoking, becomes an important 
factor for clinicians to understand. Participation in previous health behaviors such as 
smoking is not a valid reason for anyone to have suboptimal care.  
At this time there is a paucity of research to examine the effects of stigma on 
lung cancer patients. Evidence about the perception and actual social support needs of 
lung cancer patients is also lacking, especially when compared to other stigmatized 
diseases, such as HIV/AIDS, where disease-related stigma has been shown to have a 
negative effect on social support and patient/caregiver outcomes 
 A cross-sectional design was the most appropriate choice for this study to 
minimize attrition and time burden on patients with advanced lung cancer. Unfortunately 
this limits the scope of the study to a single time point and it was unable to detect 
changes in the concepts measured over the treatment trajectory. Self-report measures 
were selected to reflect the “reality” of the experience of patients with advanced lung 
cancer. All measures chosen were subjective in nature but study instruments were 
carefully selected to minimize the lack of objective data collected in the study. 
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Sample Characteristics 
 This study recruited patients with lung cancer who had received chemotherapy 
as part of their treatment. The demographic characteristics of this sample were similar 
to other samples reported in the literature when stigma was a primary variable. The 
mean age in this study was 64.45 years which is similar to the mean age of 62.15 
reported by Chambers et al.’s (2015), 64 years reported by Gonzalez & Jacobsen 
(2010, 2012), 63 years reported in Lebel et al.’s (2013) study, and 65.6 years reported 
in LoConte et al.’s (2008) study. In this study, 59.7% of patients identified as female. 
Although most studies that investigated stigma reported higher participation by women, 
the percentage varied within the literature. The percent of females in this study is lower 
than Brown-Johnson, Brodsky, & Cataldo (2015) (75.2%), Brown & Cataldo (2013) 
(100%), Cataldo & Brodsky (2013) (74%), Chambers et al. (2015) (88%), and similar to 
Carter-Harris (2014) (62.4%) and Lehto (2014) (55%). The most recent data from the 
American Cancer Society (2015) indicates the incidence and mortality rates for lung 
cancer remain higher for men than for women.  
 The majority of patients in the present study reported a smoking history (66.1%) 
which was lower than the majority of currently published studies investigating stigma in 
lung cancer. Other published studies reported higher rates of smoking history including 
Brown-Johnson, Brodsky & Cataldo (2015) (80% former smokers), Cataldo & Brodsky 
(2013) (79% current or former smokers), Cataldo, Jahan & Pongquan (2012) (79.5% 
ever smokers), and LoConte et al. (2013) (80.2% with a smoking history). Only two 
studies reported similar percentages of smoking history including Carter-Harris (2014) 
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(67.7% with a smoking history) and Gonzalez & Jacobsen (2010, 2012) (71.6% with a 
smoking history).  
Of the 62 patients included in the analysis for this study, the majority identified as 
white (87.1%) with a minority identifying as black (6.5%). This is consistent with all other 
reviewed studies investigating HRS. The percentage of patients who identified as white 
in previously published studies ranges from 82.8% (Carter-Harris, 2013) to 99% 
(Chapel, Zeibland, & McPherson, 2004). According to the U.S. Census Bureau (2014), 
72.4% of the American population is white, 12.6% is black, and 4.8% identify as Asian. 
The race demographics of this study sample indicate that minorities are 
underrepresented. This is of concern as both black men and women continue to have a 
higher incidence of lung cancer compared to white men and women as well as a higher 
mortality rate from lung cancer when compared to white men and women (American 
Cancer Society, 2015). The experience of stigma associated with a lung cancer 
diagnosis may be different for black Americans for cultural or other reasons. Efforts to 
improve minority participation in stigma studies is crucial in the future to develop a 
greater understanding of how stigma may play a role after a diagnosis of lung cancer in 
minority patients.  
 
Aims 
1. To examine the relationship between internal and external HRS, physical symptoms, 
psychological symptoms, social support, and QOL in patients with advanced lung 
cancer. 
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Associations between Stigma and Symptoms 
 This study builds on the current body of knowledge that contributes to the 
understanding of HRS as it relates to the experience of symptoms that accompany a 
lung cancer diagnosis. Unlike previously published studies, this dissertation study 
attempted to explain the association of HRS to symptoms by specifically examining two 
different types of HRS: internal stigma (self-blame) and external stigma (perception of 
blame from others).  
 Physical Symptoms. Results of this study showed no statistically significant 
correlations between internal or external HRS and physical symptoms experienced by 
patients with lung cancer. Multiple studies that specifically examine symptom burden in 
an advanced lung cancer population report that these patients experience a high 
number of symptoms related to disease or treatment (Cooley, Short & Moriarty, 2002; 
Cooley, Short & Moriarty; 2003, Iyer, Taylor-Stokes & Roughley, 2013, Iyer, Roughley, 
Rider & Taylor-Stokes, 2014; Ma et al., 2014; Tishelman et al., 2005; Tishelman, 
Petersson, Degner & Sprangers, 2007). Patients in this study, however, reported a low 
symptom burden experience. Findings from this study are inconsistent with one 
published report that found an association between physical symptoms and HRS 
(Cataldo & Brodsky, 2013). 
 A combination of factors likely explains the relatively mild symptom burden 
experienced by this study sample in comparison to other published studies. The 
MDASI-LC asks patients to rate symptom severity only in the previous 24 hours and the 
majority of patients in this sample completed the questionnaire on the day they returned 
to the clinic to receive chemotherapy, therefore, the prior 24 hours was relatively free of 
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symptoms. It is also plausible that the symptoms in this sample were consistently well 
managed by the treating physician thereby lowering the overall symptom burden 
experienced by the patients. The majority of patients in this study received care at the 
Vanderbilt-Ingram Cancer Center from the same physician.  
 Psychological Symptoms. No statistically significant correlation was found 
between the psychological symptoms of depression and anxiety and HRS. Additionally, 
internal stigma was not significantly correlated with distress. Unlike other published 
studies, patients in this sample reported few symptoms of depression or anxiety. Both 
depression and anxiety have been reported to be high in both advanced cancer 
populations (Arrieta et al., 2013; Haun et al., 2014; Lekka et al., 2014; Lie et al., 2015; 
Shi, Gu, Hou & Hu, 2014) and in lung cancer populations (Haun et al., 2014; Lekka et 
al., 2014 ).  
 Findings on the relationship between HRS and depression and HRS and anxiety 
differ from those previously published. Several studies have shown a significant 
relationship between HRS and depression (Cataldo & Brodsky, 2013; Gonzalez & 
Jacobsen, 2010, Gonzalez & Jacobsen, 2012; Lebel et al., 2013; LoConte et al., 2008) 
and HRS and anxiety (Cataldo & Brodsky, 2013; Cataldo, Jahan & Pongquan, 2012; 
LoConte et al., 2008). Other published reports have also shows that HRS plays a 
unique role in HRS experienced by patients with lung cancer (Cataldo & Brodsky, 2013; 
Gonzalez & Jacobsen, 2012).  
One reason the findings from this study may be inconsistent from previously 
published studies is because the instruments used to measure depression and anxiety 
differ from other published studies. Although the most common instrument used to 
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measure depressive and anxiety symptomology in a lung cancer population is the 
HADS, studies investigating HRS in patients with lung cancer typically selected the 
CES-D to measure depression (Brown-Johnson, Brodsky & Cataldo, 2014; Cataldo & 
Brodsky, 2013; Cataldo, Jahan & Pongquan, 2012; Chambers et al., 2015) and the 
Spielberger State Anxiety Scale (Brown-Johnson, Brodsky & Cataldo, 2014; Cataldo & 
Brodsky, 2013). At this time a large portion of the stigma literature involves one 
particular researcher (Cataldo) and this is a significant factor in the choice of 
measurement instruments used to study stigma in patients with lung cancer.  
This study specifically focused on patients with advanced lung cancer. Other 
studies investigating HRS and depression had fewer patients with advanced lung 
cancer in the sample (Gonzalez & Jacobsen, 2010, Gonzalez & Jacobsen, 2012) or 
included other types of cancer in the sample (Lebel et al., 2013). 
 Patients in this study reported mild to moderate levels of distress. This study 
found that distress was positively and significantly correlated with three questions which 
examined external HRS: 1) patient perception that others feel awkward or tense around 
them, 2) patient perception that there is a stigma with lung cancer, and 3) patient 
perception that others think less of a person with lung cancer. Although significant, 
correlations were weak. Findings from this study were consistent with other studies that 
have examined HRS and distress (Chambers et al., 2015; Lebel et al., 2013). Distress 
is an understudied phenomenon in patients with lung cancer. While multiple studies 
have investigated the incidence and influence of depression and anxiety on patients 
with lung cancer only two previously published studies have examined distress.  
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 Social Support. Social support is an understudied phenomenon in patients with 
lung cancer. In this study, social support was significantly associated with both internal 
and external HRS. There were more significant correlations between the patient’s 
reported perception of external HRS and social support than the perception of internal 
stigma and social support. Patients who reported a higher perception of external stigma 
also reported less received support from the primary caregiver as well as less general 
social support (such as having someone to talk to or someone to consult with about 
treatment related decisions). Patients who reported they blamed themselves for their 
disease (internal HRS) reported less received social support from the primary caregiver.  
This study is the first quantitative study to investigate the relationship between 
social support and HRS. One qualitative study reported that women diagnosed with lung 
cancer felt that stigma played a role in how they interacted with healthcare providers 
(Brown & Cataldo, 2013). Another qualitative study reported that the perception of HRS 
associated with lung cancer affected the way lung cancer patients interacted with their 
family, friends, and healthcare providers. The finding from this study supports the earlier 
published qualitative literature.  
 Quality of Life. A significant association was found between external HRS and 
internal HRS and QOL. Like social support, more statistically significant associations 
were found between external HRS and QOL than internal HRS and QOL. Higher levels 
of external HRS were associated with a lower quality of life in all domains (physical, 
emotional, spiritual, and intellectual) as well as overall QOL. Patients who blamed 
themselves for lung cancer reported a lower physical and emotional QOL and those 
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who felt others blamed them for lung cancer reported lower physical, intellectual, and 
overall QOL.  
When this study was first designed, no other published studies had investigated 
the association between stigma and QOL. Since that time two published studies have 
examined the relationship between lung cancer HRS and QOL. Findings from this study 
support these earlier findings (Brown-Johnson, Brodsky & Cataldo, 2014; Cataldo, 
Jahan & Pongquan, 2012).  
Brown-Johnson, Bodsky & Cataldo (2014) recruited patients who completed 
online self-report measures. The study sought to determine if HRS was negatively 
correlated with QOL and if HRS played a unique role in the QOL experienced by 
patients with lung cancer. The study found that HRS was negatively correlated with 
QOL and that stigma played a unique role in QOL in patients with lung cancer. Cataldo, 
Jahan & Pongquan (2012) conducted a cross-sectional descriptive study with 190 
participants. The results of this study found a statistically significant negative correlation 
between HRS and QOL in patients with lung cancer. Furthermore, results showed that 
HRS in patients with lung cancer played a unique and significant role in QOL over and 
above the factors of depression, age, gender, and smoking status.  
2. To examine the associations between physical symptoms and social support and 
QOL in patients with advanced lung cancer.  
 Social Support. No significant associations were found between physical 
symptoms and social support in this study. At this time no other studies have examined 
overall symptom burden or symptom experience and social support in patients with lung 
cancer.  One study investigated the relationship between the individual symptom of pain 
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and social support. Lekka et al., (2014) investigated the relationship between pain in 
patients with lung cancer and social support. In that study, pain severity and pain 
interference was significantly and negatively correlated with family support. 
 The MDASI-LC measures symptom severity on a summed scale with the rating 
of all symptoms included in the total scale score. Individual symptoms were not 
examined within the scope of this dissertation to determine if there is a relationship 
between the severity of individual symptoms (such as dyspnea or pain) and the 
perception of social support. Furthermore, symptom interference, as measured by the 
MDASI-LC, was also outside of the scope of this dissertation and the relationship 
between symptom interference and social support was not examined.  
 Quality of Life. In this study, no significant associations were found between 
physical symptoms and QOL. Findings from this study differ from the one previously 
published study in the literature. One study that investigated physical symptoms of lung 
cancer patients found that certain symptoms were a predictor of QOL, including: fatigue, 
loss of appetite, pain, and shortness of breath (Iyer, Taylor-Stokes & Roughley, 2013; 
Iyer, Roughley, Rider & Taylor-Stokes, 2014). This dissertation study investigated the 
association between physical symptoms and QOL by using a summed score of overall 
symptom severity as reported by patients. The previously published studies looked for 
associations between specific symptoms, such as fatigue or pain, and QOL. 
3. To examine the associations between psychological symptoms and social support 
and QOL in patients with advanced lung cancer. 
 Depression and Social Support. In this study, no significant relationship was 
found between depression and social support in patients with advanced lung cancer. 
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The influence and relationship of depression and social support found in this study is 
inconsistent from two previously published studies ( Shi, Gu, Hou & Hu, 2014; Walker, 
Zona & Fisher, 2005). Shi, Gu, Hou & Hu (2014) conducted a study with 104 inpatients 
with NSCLC in China and multivariate analysis showed that social support was a 
predictor of self-reported depression in patients with lung cancer. Walker, Zona & Fisher 
(2005) investigated depression and social support in 119 surgical patients with Stage I 
or II lung cancer and their results showed a significant relationship between directive 
instrumental social support and depressive symptoms but no relationship between non-
directive social support and depressive symptoms.  
There are several major differences between this dissertation study and the two 
studies that previously investigated depression and social support that may explain the 
conflicting results. The patients in this study were treated in an outpatient clinic at a 
comprehensive cancer care center in the United States whereas the patients in the 
study conducted by Shi, Gu, Hou & Hu (2014) were treated at an inpatient facility and 
lived in China. Furthermore, this dissertation study measured social support in two 
ways, main caregiver support and general social support, whereas the study by Shi, Gu, 
Hou & Hu (2014) used one general measure of social support. The major differences 
between this study and the study conducted by Walker, Zona & Fisher (2005) is that this 
dissertation study recruited participants with advanced lung cancer who were receiving 
chemotherapy as part of their treatment plan and whereas Walker, Zona & Fisher 
(2005) recruited patients who had Stage I or II disease and who received surgery 
instead of chemotherapy as treatment.   
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Depression and Quality of Life. No relationship was found between depression 
and QOL in this study which is inconsistent with previous findings. Two previously 
published studies have reported an association between depression and QOL in 
patients with lung cancer (Arrieta et al., 2013; Brown-Johnson, Brodsky & Cataldo, 
2014). Arrieta et al. (2013) investigated the role of depression and QOL in patients with 
advanced lung cancer and found a negative correlation between the two variables. 
Additionally, Brown-Johnson, Brodsky & Cataldo found a significant negative correlation 
between depression and QOL. It is unclear why results in this dissertation study differ 
from those previously published in the literature though it may be that, overall, patients 
in this study had a very low incidence of depression compared to other published 
studies.  
Anxiety and Social Support. No significant relationship between anxiety and 
social support was found in this dissertation study. Only one other published study has 
investigated the relationship between anxiety and social support. The previous study 
found a significant negative correlation between state anxiety and trait anxiety in 
patients with lung cancer (Lekka et al., 2014). Additionally, family support was a unique 
contributor to the variance in anxiety (Lekka et al., 2014). One major difference between 
the previously published study and this dissertation is that the previous study was 
conducted in Greece. Cultural perceptions of anxiety or family support may be 
perceived differently in different countries. Moreover, patients in this dissertation study 
reported low overall levels of anxiety when compared to previous reports on incidence 
of anxiety in patients with lung cancer.  
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Anxiety and Quality of Life. Anxiety was not correlated with QOL and this finding 
is inconsistent with one previously published study examining anxiety and QOL in 
patients with advanced lung cancer. Arrieta et al. (2013) found that anxiety was 
negatively correlated with QOL. The previously published study was conducted in 
Mexico where patients may have different perceptions of anxiety or QOL as it relates to 
a diagnosis of lung cancer and patients in this dissertation study reported lower levels of 
anxiety than is typically seen in the literature. 
 Distress and Social Support. Distress was not significantly associated with social 
support in this study. One previous study examined psychological distress and social 
support and found that distress was negatively correlated with emotional support (Ell, 
Nishmoto, Medianski, Mantell & Hamovitch, 1991). The previously published report 
examining distress and social support included a wide variety of cancer types and only 
17% of the sample was reported to have lung cancer.  
Distress and Quality of Life. A significant negative correlation was found in this 
study between distress and four domains of QOL (physical, emotional, spiritual, and 
intellectual) as well as overall QOL. No previously published studies have examined 
both distress and QOL in patients with lung cancer. One study that examined the rates 
of distress in a large cohort of 14 different cancer diagnoses (n=4496) found that of all 
cancer sites studied, patients with lung cancer reported the highest levels of 
psychological distress (43.4%) (Zabora, Brintzenhofe, Curbow, Hooker & Piantadosi, 
2001).  
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Study Strengths and Limitations 
This dissertation is unique in that it is the first study to look at HRS specifically in 
an advanced lung cancer population. Furthermore, it is the first quantitative study to 
examine possible associations between stigma and social support and the first study to 
examine the relationship between physical symptoms and social support. First, major 
strengths of this study are discussed in the areas of methodology and research content 
and then limitations are discussed.  
Strengths 
 Strengths in Methodology. Although other studies have been published regarding 
HRS in lung cancer this is the first study to limit the sample to patients with advanced 
lung cancer. Patients with advanced lung cancer have a unique experience of 
symptoms, treatment, and outcomes therefore it is important to investigate stigma 
specifically within this population. This study was the first known quantitative study to 
measure and investigate associations between external and internal HRS and social 
support in patients with lung cancer. Additionally, this was the known first study to look 
at possible connections between physical symptoms associated with a diagnosis of lung 
cancer and social support. This study was also the first known study investigating HRS 
in patients with lung cancer to use the HADS to measure psychological symptoms. The 
HADS can be used as a diagnostic tool to indicate depression and anxiety in a patient 
whereas the CES-D, the most commonly used measure of depression in HRS stigma 
studies, can only indicate depressive symptomology. This difference in measurement 
tools allows for a more accurate description of depression and anxiety within this 
population. In addition to recruitment from a comprehensive cancer center, patients 
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were recruited nationwide for online participation in this study via two organizations, 
LUNGevity and the Lung Cancer Alliance. Recruiting patients from a nationwide sample 
ensured the perceptions of HRS were included from a variety of regions within the 
United States. Other studies investigating HRS in patients with lung cancer have either 
used an online only sample or a clinic-based only sample.  
 Strengths in Research Content. This study identified that patients with lung 
cancer who perceive greater levels of external or internal HRS also perceive less 
support from the main caregiver as well as general social support. This finding indicates 
that patients who perceive a greater HRS due to their diagnosis may be at risk for 
decreased care or support at a time of great need. Because many patients with 
advanced cancer must rely on a main caregiver for the bulk of care in the home setting 
during intensive chemotherapy treatments or during end-of-life care, this finding is 
clinically important. Nurses can play a key role in assessing patients for the perception 
of external or internal HRS and how these perception influence relationship between the 
patient and the main care provider in the home setting and the interactions of the patient 
with the community at large.  
Limitations 
 This study has several limitations. (1) External validity. A convenience sampling 
method was used in this study rather than a random sample of patients. The majority of 
patients were recruited from a single comprehensive cancer care center from the clinic 
of a single provider. Although nationwide convenience sampling was also utilized there 
may not have been enough national representation to make these results generalizable 
to a nationwide sample. Furthermore, this sample was limited in ethnic diversity with 
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primarily white and black participants. Results may not be generalizable to other 
minority populations. (2) Internal validity. In a cross-sectional design, a main threat to 
internal validity is establishing cause. In this study only associations between variables 
were investigated and therefore statements about causality cannot be made. For 
example, we can say there is a relationship between HRS and social support in patients 
with lung cancer but we cannot say if the perception of HRS is what led to fewer 
available social supports or if fewer available social supports gave patients the 
perception that others blamed them for the diagnosis of lung cancer. The sample in this 
study is too small for multivariate analysis. The concept of HRS in patients with lung 
cancer is complex and therefore a multivariate analysis would offer more explanation 
than univariate analysis. (3) Measurement validity. HRS in patients with lung cancer has 
been measured using a wide variety of instruments. The most common instrument to 
date is the Cataldo Lung Cancer Stigma Scale. This length of this measure, however, 
was deemed inappropriate for this study, therefore a different instrument was used. The 
HRS measurement tool for this study has only been previously used in men who 
received care at the VA. Additionally, the MDASI-LC only captures the symptom 
experience of patients within the previous 24 hours. This brief period may not accurately 
reflect the true, overall symptom experience for patients with advanced lung cancer. (4) 
Other possible confounding factors. All patients in this study received chemotherapy as 
part of a treatment plan. Current and past chemotherapy regimens varied between 
participants and were dependent on time since diagnosis. Some participants in this 
study had only received one dose of chemotherapy while others had a history of 
multiple chemotherapy drugs, a history of radiation therapy, and a history of 
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experimental treatment through clinical trials. Therefore, a multitude of unknown 
confounding factors may influence the results of this study.  
 
Implications 
 The role of HRS within the experience of patients with lung cancer remains an 
understudied phenomenon. Published literature demonstrates inconsistencies in some 
results as well as large inconsistencies in measurement tools used to understand the 
phenomenon and the factors that may influence HRS. Clinicians have little data from 
which to develop knowledge or understanding of HRS in patients with lung cancer and 
how HRS may affect the experience of patients with advanced lung cancer. This 
dissertation study, based on the theory of Unpleasant Symptoms, examined the 
relationship between internal and external HRS and psychological symptoms, physical 
symptoms, social support, and QOL to fill in gaps identified in the literature related to 
the phenomenon.  
 The most critical positive finding from this study was the relationship between 
internal and external HRS and social support. Results from this study identified that 
patients who had a higher perception of external HRS had a lower perception of support 
from the main caregiver as well as fewer general available social supports. 
Furthermore, patients who blamed themselves for their disease also perceived less 
support from the main caregiver. This finding is especially troublesome considering the 
large symptom burden typically experienced by patients with advanced lung cancer as 
they progress towards the end of life. Patients who have an increased perception of 
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HRS may be receive suboptimal care in the home setting which will influence patient 
QOL as well as quality of dying.  
 This study also contributed to the growing body of knowledge that HRS is related 
to the QOL experienced by patients with lung cancer. Results from this study were 
consistent with those previously published but this was the first study to exclusively 
focus on patients with advanced lung cancer. QOL becomes extremely important as 
patients begin to face the possibility of dying. Even though currently available therapies 
can extend the life of patients with lung cancer almost all patients with advanced 
disease will eventually succumb to the disease or a complication of advanced disease 
rather than die from another cause. For this reason it is important for clinicians to 
understand factors that may influence patient QOL and work to improve QOL as part of 
ongoing palliative care for these patients. 
 Finally, this was one of the few studies that examined the relationship between 
HRS in lung cancer patients and distress in addition to the more traditionally studied 
psychological symptoms of depression and anxiety. Although the level of distress 
reported by participants in this study was relatively mild, it was significantly associated 
with external HRS and physical, emotional, intellectual, spiritual, and overall QOL. This 
finding indicates that the level of distress experienced by patients with lung cancer may 
be a better measure for clinicians to use when assessing the psychological state of 
patients with lung cancer as distress may be more indicative of mental health and well-
being in patients with advanced lung cancer than depression or anxiety. 
 Important negative findings from this study include no significant association 
between depression or anxiety and HRS and no association between physical 
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symptoms and HRS. Findings regarding depression and anxiety in this study are not 
consistent with previously published literature and may indicate that inappropriate 
measures of psychological symptoms are being used or that the association between 
depression and anxiety and HRS have been overstated within the literature. The finding 
that HRS and physical symptoms are not associated with one another indicates that 
physical symptoms may not be a part of the experience of stigma within this population. 
These results, however, must be interpreted with caution due to the limitations of the 
measurement tool used to evaluate physical symptoms.  
 There are multiple implications for the findings of this study. Clinicians, especially 
nurses, must possess the knowledge to understand HRS within the context of a lung 
cancer diagnosis and how the perception of HRS influences the experience of the 
patient, especially the availability of social support from a main caregiver or support 
from other sources, such as family, friends, or the wider community. Healthcare 
professionals should be aware that HRS is a common experience for patients with lung 
cancer, regardless of smoking status, and be prepared to discuss the perception of 
HRS with patients and their main caregivers.  
  
Recommendations for Future Research 
 The results of this dissertation study can be used to guide future research in the 
following ways: 
 Although some patients for this study were recruited online to increase 
geographic diversity and diversity in care setting, the majority of patients were recruited 
from one comprehensive cancer care center in a state with a high rate of smoking and a 
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high rate of lung cancer compared to other states. Furthermore, the majority of 
participants in this study were white. Future studies would benefit from recruiting from 
multiple clinical sites with greater geographic diversity and diversity in the type of clinic 
in which patients receive care, for example, from smaller community clinics. Efforts 
should also be made to include a larger number of minority participants in studies 
regarding HRS in advanced lung cancer.  
 HRS and support from the main caregiver as well as general social support were 
shown to be associated in this study. This finding suggests that it is essential to conduct 
future research to discover what types support are utilized by patients with lung cancer 
and which supports are the most beneficial for these patients.  
 Because the bulk of care for patients with advanced lung cancer is provided at 
home it is important to first conduct descriptive studies that investigate how patients 
perceive support from a main caregiver in order to build a body of knowledge about 
social support in patients with lung cancer. A qualitative study would be beneficial to 
understand the experience of support from a main caregiver for patients with lung 
cancer as well as to understand what types of social support from the main caregiver 
are most important to patients with advanced lung cancer. A qualitative study would 
also be beneficial to describe the types of general social support that patients with 
advanced lung cancer find helpful and to which they have access. Finally, a qualitative 
study could explore the lived experience of HRS as it relates to social support in 
patients with advanced cancer.  
There is a need to develop a took to be used in a clinical setting that would 
include a checklist of specific types of social support most commonly received from a 
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main caregiver as well as a scale to determine the level of specific supports received. 
Nurses and other healthcare professionals could utilize this tool to evaluate patients and 
caregiver dyads to determine which patients may be at risk for sub-optimal care at 
home and to provide appropriate interventions to bolster at home support and care for 
patients with advanced lung cancer. Descriptive studies are needed to clarify what 
specific supports within the community lung cancer patients have access to and which 
supports they utilize more frequently, such as monthly lung cancer support meetings, 
church, or informal gatherings with friends. These studies need to further address how 
HRS may influence the patient’s by examining multiple factors that may influence the 
patient’s utilization of social support. 
Intervention studies are needed to help patients with advanced lung cancer 
address and reduce feelings of stigma and bolster access to social support at home and 
within the community. Furthermore, interventions are needed to improve QOL for these 
patients as they move through the stages of care and towards end of life.  
 Study findings also indicate that the MDASI-LC may not accurately capture or 
reflect the true symptom experience of patients with advanced lung cancer. There is a 
need to develop a validated scale based on the Theory of Unpleasant Symptoms that 
captures the timing, intensity, distress and quality of the symptoms commonly 
experience by patients with advanced lung cancer. Furthermore, the scale should 
assess patient symptoms within a time frame of more than the previous 24 hours so that 
the overall picture of patient symptoms can be captured by the clinicians and 
appropriately treated.  
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 Due to conflicting results reported within the literature, more studies are needed 
to address the role between HRS and depression, anxiety, and distress. Studies are 
also needed to address the relationship between HRS and function in patients with lung 
cancer.  
 New knowledge generated from these proposed studies would inform healthcare 
professionals, such as bedside nurses and nurse practitioners, and could make 
significant contributions to improving the experience of patients with advanced lung 
cancer in the areas of HRS, social support, and the management of physical and 
psychological symptoms.  
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APPENDIX A 
PATIENT CONTACT SCRIPT 
PATIENT CONTACT SCRIPT DISTANCE PARTICIPANTS 
“Thank you for calling about our study. I need to get some basic contact information. Is 
that okay?”   
Can I have the correct spelling of your name?___________________________ 
Your home phone number is  ___________________________ 
Your work phone number is ______________________________  
What is your correct street address? ___________________________ 
What is your correct city and state? __________________________  
Do you want to give us your email address? 
___________________________________ 
How old are you? _________ (if not 18, or older,  “Thank you for allowing me 
to verify the information, but right now our studies require that you be over 18 years 
old”. and go to #15. 
“Thank you for giving me that information. I would like to tell you about our study if 
you have a few minutes.” 
This study is about stigma that patients with lung cancer may or may not feel. I am 
interested in finding out the different ways that stigma may influence the way patients 
with lung cancer feel. 
 
You will: 
 Receive an invitation by email to take several surveys online 
 Be asked about demographic and medical history information 
I will have you sign a medical chart release form so that your doctor can send me 
your medical records specific to your lung cancer diagnosis and any treatments 
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you may have had. This may include information about biopsies you may have 
had or chemotherapy or radiation treatments. 
 
If you think you are interested, I will need to ask you several questions to see if you 
qualify for the study. 
 
 
Subject: RedCap Survey Invitation 
Thank you for agreeing to participate in Lee Ann Jarrett’s lung cancer research study.  
This is your invitation to complete your survey in RedCap.  Please complete and submit 
this survey in the next week. 
If you need to leave your survey and return later, please click the “Save and Return 
Later” tab and make note of your validation code.  If you lose your validation code, call 
the study office at 615-343-6313 or 1-800-xxx-xxxx. You can also email us at 
lee.a.jarrett@vanderbilt.edu and we’ll provide it to you.  When you are ready to finish 
your survey, click on this survey link and enter your code to continue where you left off. 
 
PATIENT CONTACT SCRIPT LOCAL PARTICIPANTS 
“Hello Mr./ Ms./ Mrs. ____________(state the person’s name) I am ___________(state 
your name). I am __________ a student at the Vanderbilt School of Nursing.” 
 
“Your doctor, __________(insert Dr’s name) has asked me to talk to you about a 
research study that is available to you. May I have a few minutes of your time?” If no, 
thank them and leave.  
 
If yes, “Thank you. The study I would like to tell you about does not involve medication 
and will not impact your cancer treatment.  We are trying to learn more about how 
people feel after a diagnosis of lung cancer.“ 
 
 Then review the following bullet points, giving them time to ask questions. 
   
 
129 
 
 
1. What will happen and how long will you be in the study? 
 
If you agree to be in the study, you will fill out surveys one time. 
 
2. Procedures to be followed and approximate duration of the study: 
We will talk to you and ask about: 
 Where you live, if you have insurance, do you work, what is your 
household income 
 Alcohol and tobacco use. 
We will write these answers down. 
 
You will fill out forms (we will help you  if you need us to) that asks about:  
 Stigma: How you view yourself and how others may view you. 
 Any physical problems you may have with pain, fatigue, breathing, and 
appetite. 
 Any emotional problems you have such as feeling sad or anxious. 
 What kinds of support you have available. 
 How well you are able to care for yourself. 
 How you feel about the overall quality of your life. 
 
 Review of Records (We will do this the whole time you are in the study. The 
information we write down comes from your standard medical care record and reflects 
services that are not done for research only.) 
 We will look at and record your medical history on our forms. This will include 
things like any heart, stomach, bone, or other problems you may have.  
 We will record any medications you are taking during your treatment. 
 We will record any problems (toxicities) that your doctor has recorded that 
may be related to your treatment. 
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APPENDIX B 
SCREENING FORM 
Eligibility Criteria-Checklist For Distance Participants 
Health-Related Stigma in Advanced Lung Cancer 
 
Criteria: 
1) Is the patient age 18 or 
over? 
If yes go to #2 If no STOP 
2) Has the patient received 
chemotherapy for 
treatment of a primary 
lung tumor?  
If yes go to # 3 If no STOP 
3) Does the patient speak 
English? 
If yes go to # 4 If no STOP 
4) Did the patient pass the 
Short Portable Mental 
Status Questionnaire? 
If yes go to #5 If no STOP 
5) Does patient have any 
other active cancer?  
If no go to #6 If  yes STOP 
6) Is the patient enrolled in 
hospice? 
If no patient meets 
criteria and you can 
discuss the study with 
the patient. 
If yes STOP 
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APPENDIX C 
DEMOGRAPHIC AND BACKGROUND INFORMATION 
1. What is your birthdate? 
____/____/__________ (month/day/year) 
 
2. Gender: 
(1) Female ____(2) Male____ 
(3) Other____ (4) Do not care to respond ____ 
 
3. What is your race? 
(1) American Indian/Alaskan Native ____ 
(2) Asian ____ 
(3) Native Hawaiian or Other Pacific Islander ____ 
(4) Black or African American ____ 
(5) White ____ 
Nation of Origin: _________________________ 
 
4. What is the highest grade of education you completed? (Please circle) 
1 2 3 4 5 6 7 8 9 10 11 12(high 
school) 13 14 15 16(college) 17 18 (master) 19 20(doctorate) 
 
5. What is your marital status: 
(1) Single ____ 
(2) Single, living with partner ____ 
(3) Married ____ 
(4) Widowed ____ 
(5) Other ____ 
 
6. What is your marital status? 
(1) Employed full time ____ 
(2) Employed part time ____ 
(3) Homemaker ____ 
(4) Retired ____ 
(5) Unemployed ____ 
(6) Other ____ 
Vocation __________________________________________________ 
 
7. What best describes your area of residence? 
(1) City ____ (2) Country ____ (3) Other ____ 
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8. Health Maintenance 
8.1 Smoking 
(1) No 
(2) Yes ____ (Tobacco __ or Marijuana __or __________) 
____years _____cigarettes per day 
(3) Quit 
(4) Not Quit 
_____cigarettes per day (Current) 
 
8.2 Drinking Alcohol 
(1) No ____ 
(2) Yes ____ 
_____years _____ times per week 
(3) Quit 
(4) Not Quit _____ 
_____ times per week (Current) 
 
9. What is your insurance coverage? 
(1) Medicare____ (2) Medicaid ____ 
(3) TennCare ____ (4) Private Insurance ____ 
(5) HMO ____  (6) None _____ 
(7) Other _____ 
 
10. Do you have any medical problems? 
(1) No 
(2) Yes (e.g., HBP, BM, Obesity, Injury History) __________________________ 
 
11. What is your yearly household income? 
(1) $10,000 or less ____ 
(2) $10,001 to $20,000 ____ 
(3) $20,001 to $30,000 ____ 
(4) $30,001 to $40,000 ____ 
(5) $40,001 to $50,000 ____ 
(6) $50,001 to $60,000 ____ 
(7) Over $60,000 ____ 
(8) Do not care to respond ____ 
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APPENDIX D 
 
INTERNAL AND EXTERNAL STIGMA SCALE 
 
Please read the following questions carefully. Circle the number that best represents 
how you true you find the statement. 
 
 Not at all 
True 
1 
A Little 
True 
2 
Somewhat 
True 
3 
Completely 
True 
4 
1. I feel that some people avoid me because 
I have lung cancer. 
1 2 3 4 
2. I feel that some people feel awkward and 
tense around me because I have lung 
cancer. 
1 2 3 4 
3. I feel there is a stigma that goes with 
having my condition. 
1 2 3 4 
4. I feel that most people think less of a 
person who has lung cancer. 
1 2 3 4 
5. I feel I am to blame for my illness. 1 2 3 4 
6. I feel other people think I am to blame for 
my illness. 
1 2 3 4 
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APPENDIX E 
SOCIAL CONTRAINTS SCALE 
Sometimes, even when your spouse or partner has good intentions, he may say or do 
things that upset you. Think about the PAST MONTH and indicate how often your 
spouse/partner did the following things. 
Use the scale that ranges from 0-10 
How often in the past month has your spouse/partner/caregiver… 
1. Changed the subject when you tried to discuss your illness? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
2. How often did it seem your spouse/caregiver did not understand your situation? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
3. How often did your spouse/caregiver minimize your problems? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
4. How often did your spouse/caregiver seem to be hiding his/her feelings? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
5. How often did your spouse/caregiver act uncomfortable when you talked about your 
illness? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
6. How often in the past month has your spouse/caregiver trivialized your problems? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
7. How often did your spouse/caregiver complain about his/her own problems when you 
wanted to share your own? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
8. How often did your spouse/caregiver act cheerful around you to hide his/her true 
feelings and concerns? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
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9. How often did your spouse/caregiver tell you not to worry so much about your 
health? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
10. How often did your spouse/caregiver tell you to try not to think about the cancer? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
11. How often did you get the idea that your spouse/caregiver didn’t want to hear about 
your cancer? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
12. How often did your spouse/caregiver make you feel as though you had to keep your 
feelings about your cancer to yourself, because they made him/her upset? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
13. How often did your spouse/caregiver make you feel as though you had to keep your 
feelings about your cancer to yourself, because they made him/her upset? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
 
14. How often did your spouse/caregiver let you down by not showing you as much love 
and concern as you would have liked? 
0 1 2 3 4 5 6 7 8 9 10 
Never          Always 
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APPENDIX F 
 
M.D. ANDERSON SYMPTOM INVENTORY SCALE—LUNG CANCER 
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APPENDIX G 
NCCN DISTRESS THERMOMETER 
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APPENDIX H 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
This questionnaire is designed to help your clinician to know how you feel. Read 
each item below and underling the reply which comes closest to how you have been 
feeling in the past week. Ignore the numbers printed at the edge of the 
questionnaire. 
 
Don’t take too long over your replies, your immediate reaction to each item will 
probably be more accurate than a long, thought-out response.  
 
I feel tense or “wound up” 
Most of the time 
A lot of the time 
From time to time, occasionally 
Not at all 
 
I still enjoy the things I used to enjoy 
Definitely as much 
Not quite so much 
Only a little 
Hardly at all 
 
I get a sort of frightened feeling as if something awful is about to happen 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all 
 
I can laugh and see the funny side of things 
As much as I always could 
Not quite so much  now 
Definitely not so much now 
Not at all 
 
Worrying thoughts go through my mind 
A great deal of the time 
A lot of the time 
Not too often 
Very little 
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I feel cheerful 
Never  
Not often 
Sometimes 
Most of the time 
 
I can sit at east and feel relaxed 
Definitely 
Usually 
Not often 
Not at all 
 
I feel as if I am slowed down 
Nearly all the time 
Very often 
Sometimes 
Not at all 
 
I get a sort of frightened feeling like “butterflies” in the stomach 
Not at all 
Occasionally 
Quite often 
Very often 
 
I have lost interest in my appearance 
Definitely 
I don’t take as much care as I should 
I may not take quite as much care 
I take just as much care as ever 
 
I feel restless as if I have to be on the move 
Very much indeed 
Quite a lot 
Not very much 
Not at all 
 
I look forward with enjoyment to things 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 
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I get sudden feelings of panic 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
I can enjoy a good book or radio or television programme 
Often 
Sometimes 
Not often 
Very seldom 
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APPENDIX I 
MEDICAL OUTCOMES SURVEY—SOCIAL SUPPORT SURVEY 
 
People sometimes look to others for companionship, assistance, or other types of 
support. How often is each of the following kids of support available to you if you 
need it? Circle one number on each line.  
 
 None of 
the time 
A little of 
the time 
Some of 
the time 
Most of 
the time 
All of 
the time 
Emotional/informational support  
Someone you can count on to listen 
to you when you need to talk 
1 2 3 4 5 
Someone to give you information to 
help you understand a situation 
1 2 3 4 5 
Someone to give you good advice 
about a crisis 
1 2 3 4 5 
Someone to confide in or talk to 
about yourself or your problems 
1 2 3 4 5 
Someone whose advice you really 
want 
1 2 3 4 5 
Someone to share your most 
private worries and fears with 
1 2 3 4 5 
Someone to turn to for suggestions 
about how to deal with a personal 
problem 
1 2 3 4 5 
Someone who understands your 
problems 
1 2 3 4 5 
Tangible support 1 2 3 4 5 
Someone to help you if you were 
confined to bed 
1 2 3 4 5 
Someone to prepare your meals if 
you were unable to do it yourself 
1 2 3 4 5 
Someone to help with daily chores 
if you were sick 
1 2 3 4 5 
Affectionate support  
Someone who shows you love and 
affection 
1 2 3 4 5 
Someone to love and make you feel 
wanted 
1 2 3 4 5 
Someone who hugs you 1 2 3 4 5 
Positive social interaction 1 2 3 4 5 
Someone to have a good time with 1 2 3 4 5 
Someone to get together with for 
relaxation 
1 2 3 4 5 
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Someone to do something 
enjoyable with 
1 2 3 4 5 
Additional item  
Someone to do things with to help 
you get your mind off things 
1 2 3 4 5 
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APPENDIX J 
QUALITY OF LIFE SCALE (LINEAR ANALOG SELF-ASSESSMENT) 
Directions: Please circle the number (0-10) best reflecting your response to the 
following that describes your feelings during the past week, including today. 
 
1. How would you rate your physical well being over the past week? 
This questions refers to such things as fatigue, activity, etc 
0 1 2 3 4 5 6 7 8 9 10 
As bad as        as good as it can be 
It can be 
 
2. How would you rate your emotional well being over the past week? 
This question refers to such things as depression, anxiety, stress, etc. 
0 1 2 3 4 5 6 7 8 9 10 
As bad as        as good as it can be 
It can be 
 
3. How would you rate your spiritual well being over the past week? 
This question refers to such things as a sense of meaning and purpose, relationship 
with God, etc. 
0 1 2 3 4 5 6 7 8 9 10 
As bad as        as good as it can be 
It can be 
 
4. How would you rate your intellectual well being over the past week? 
This question refers to such things as the ability to think clearly, to concentrate, to 
remember, etc. 
0 1 2 3 4 5 6 7 8 9 10 
As bad as        as good as it can be 
It can be 
 
5. how would you rate your overall well being over the past week? 
0 1 2 3 4 5 6 7 8 9 10 
As bad as        as good as it can be 
It can be 
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